{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# CDSS Demo"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Initial Imports"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 1,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from dotenv import load_dotenv\n",
    "\n",
    "# Load environment variables from the .env file\n",
    "load_dotenv()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_core.messages import AIMessage, SystemMessage\n",
    "from src.custom_config.state_schema import CustomState\n",
    "from src.graph_compilation import *\n",
    "from src.llm_config import *"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Run the Virtual Assistant"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Compile the graph\n",
    "graph = compile_graph()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<IPython.core.display.Image object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# from IPython.display import Image, display\n",
    "\n",
    "# display(Image(graph.get_graph().draw_mermaid_png()))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Execute the Agentic RAG"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "#######################################################\n",
      "######## CURRENT NODE: PATIENT PROCESSOR NODE #########\n",
      "#######################################################\n",
      "\n",
      "Please, select a patient to process:\n",
      "\n",
      "Available Patients: 1 to 20\n",
      "\n",
      " - Patient Patient 1 loaded successfully.\n",
      "{'Demographic': {'PATIENT': 1, 'Age': 45, 'Sex': 'female', 'Weight (kg)': 65, 'Height (cm)': 165}, 'Patient history': {'Cancer (any type)': 'no', 'Heart failure': 'no', 'COPD': 'no', 'Chronic Cardiopulmonary Disease': 'missing'}, 'Absolute Contraindications for ': {'Haemorragic stroke (previous 6 months)': 'no', 'Unknown-origin ischemic stroke (previous 6 months)': 'no', 'Central nervous system neoplasm': 'no', 'Major trauma (previous 3 weeks)': 'no', 'Major surgery (previous 3 weeks)': 'no', 'Bleeding diathesis': 'no', 'Active bleeding': 'missing'}, 'Relative Contraindications for ': {'Transient ischemic attack (previous 6 months)': 'no', 'Oral anticoagulation': 'no', 'Pregnancy': 'missing', 'First postpartum week': 'no', 'Non compresible puncture sites': 'no', 'Traumatic resuscitation': 'no', 'Refractory hypertension (SBP>180mmHg)': 'no', 'Advanced liver disease': 'no', 'Infective endocarditis': 'no', 'Active peptic ulcer': 'no'}, 'Physical Examination': {'Systolic blood pressure (SBP)': 120, 'Diastolic blood pressure (DBP)': 86, 'Hypoperfusion': 'missing', 'Cardiac frequency': 97, 'Respiratory frequency': 20, 'Temperature (C)': 36.0, 'Altered mental status': 'no', 'Glasgow scale': 15, 'Oxygen saturation (%)': 90}, 'Echocardiography': {'RV dysfunction': 'no', 'RV/LV diameter ratio': '<1', 'Tapse': 'Not Available', 'Mcconell_sign': 'Not Available', 'Right heart trombi': 'Not Available', 'IVC diameter (cm)': 'Not Available', 'IVC inspiratory collapsibility': 'Not Available', 'TAPSV': 'Not Available'}, 'CTPA': {'Pulmonary embolism': 'yes', 'RV/LV diameter ratio': 'Not Available', 'Contrast reflux int iv': 'Not Available'}, 'Laboratory Test': {'Troponin elevated': 'Not Available', 'NtproBNP elevated': 'Not Available', 'Creatinine (mg/dL)': 0.9, 'CrCl (mL/min)': 95}}\n",
      "\n",
      "######################################################\n",
      "######## CURRENT NODE: QUERY INPUT NODE ##############\n",
      "######################################################\n",
      "\n",
      "Please type your query, or write 'Goodbye' if you want to end the session:\n",
      "\n",
      "###############################################\n",
      "####### CURRENT NODE: ORCHESTRATOR NODE #######\n",
      "###############################################\n",
      "\n",
      "### User Query Detected: How to calculate the risk of early mortality of a TPE patient ###\n",
      "### LLM Response: guidelines consultation request ###\n",
      "### Next Action Decided: guidelines consultation request ###\n",
      "\n",
      "####################################################\n",
      "######## CURRENT NODE: QUERY SOLVER NODE ###########\n",
      "####################################################\n",
      "\n",
      "##### Processed Retrieval Queries #####\n",
      "[]\n",
      "\n",
      "### LLM Response: content='' additional_kwargs={'tool_calls': [{'id': 'call_5lgDqOAtKFig2iBLVpo033VM', 'function': {'arguments': '{\"query\":\"risk assessment early mortality pulmonary embolism\",\"top_k\":5,\"reranking\":true,\"top_k_rerank\":3,\"include_refs\":true}', 'name': 'retrieval_tool'}, 'type': 'function'}], 'refusal': None} response_metadata={'token_usage': {'completion_tokens': 45, 'prompt_tokens': 1524, 'total_tokens': 1569, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4.1-mini-2025-04-14', 'system_fingerprint': 'fp_6f2eabb9a5', 'id': 'chatcmpl-BrJty1iRF1DMu464qwIup83JFinqA', 'finish_reason': 'tool_calls', 'logprobs': None} id='run--54cb31d1-4674-4003-b894-ac4aca3fdb50-0' tool_calls=[{'name': 'retrieval_tool', 'args': {'query': 'risk assessment early mortality pulmonary embolism', 'top_k': 5, 'reranking': True, 'top_k_rerank': 3, 'include_refs': True}, 'id': 'call_5lgDqOAtKFig2iBLVpo033VM', 'type': 'tool_call'}] usage_metadata={'input_tokens': 1524, 'output_tokens': 45, 'total_tokens': 1569, 'input_token_details': {'audio': 0, 'cache_read': 0}, 'output_token_details': {'audio': 0, 'reasoning': 0}} ###\n",
      "\n",
      "ACTIVATING RETRIEVAL TOOL\n",
      "\n",
      "######################################################\n",
      "######## CURRENT NODE: RETRIEVAL TOOL NODE #############\n",
      "########################################################\n",
      "\n",
      "Retrieval Tool Invoked with the following parameters:\n",
      "\n",
      "Query: risk assessment early mortality pulmonary embolism\n",
      "\n",
      "Top K: 5\n",
      "\n",
      "Reranking: True\n",
      "\n",
      "Top K Rerank: 3\n",
      "\n",
      "Include References: True\n",
      "\n",
      "##### Retrieved Documents #####\n",
      "[\"{'Figure/Table/SupplementaryTable': 'Table 8', 'References': 'Figure 3', 'Section': '5 Assessment of pulmonary embolism severity and the risk of early death', 'Subsection': '5.6 Prognostic assessment strategy', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '2bf89016-5515-4b96-9e26-dc61e3c37a2a', 'source_file': 'Protocolo_v1_images.md'}\\n\", \"{'References': 'Table 8, section 7, Figure 6', 'Section': '5 Assessment of pulmonary embolism severity and the risk of early death', 'Subsection': '5.6 Prognostic assessment strategy', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '03f717c9-1f3f-4086-94b9-e753fbbe20a9', 'source_file': 'Protocolo_v1_images.md'}\\n\", \"{'Section': '5 Assessment of pulmonary embolism severity and the risk of early death', 'Subsection': '5.5 Integration of aggravating conditions and comorbidity into risk assessment of acute pulmonary embolism', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '8e9e9ecf-0658-4e6d-be15-aed893865905', 'source_file': 'Protocolo_v1_images.md'}\\n\", \"{'Figure/Table/SupplementaryTable': 'Figure 3', 'Section': '4 Diagnosis', 'Subsection': '4.9 Echocardiography', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': 'd27c4071-516e-4610-af7a-d2365e681201', 'source_file': 'Protocolo_v1_images.md'}\\n\", \"{'Figure/Table/SupplementaryTable': 'Figure 6', 'References': 'Figure 3', 'Section': '7 Integrated risk-adapted diagnosis and management', 'Subsection': '7.2.3 Management of low-risk pulmonary embolism: triage for early discharge and home treatment', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': 'b5a6f503-93b1-4ff3-9f9f-872a60d9d75e', 'source_file': 'Protocolo_v1_images.md'}\\n\"]\n",
      "\n",
      "Tool call response: \n",
      "Retrieved Docs in tool: [\"{'Figure/Table/SupplementaryTable': 'Table 8', 'References': 'Figure 3', 'Section': '5 Assessment of pulmonary embolism severity and the risk of early death', 'Subsection': '5.6 Prognostic assessment strategy', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '2bf89016-5515-4b96-9e26-dc61e3c37a2a', 'source_file': 'Protocolo_v1_images.md'}\\n\", \"{'References': 'Table 8, section 7, Figure 6', 'Section': '5 Assessment of pulmonary embolism severity and the risk of early death', 'Subsection': '5.6 Prognostic assessment strategy', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '03f717c9-1f3f-4086-94b9-e753fbbe20a9', 'source_file': 'Protocolo_v1_images.md'}\\n\", \"{'Section': '5 Assessment of pulmonary embolism severity and the risk of early death', 'Subsection': '5.5 Integration of aggravating conditions and comorbidity into risk assessment of acute pulmonary embolism', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '8e9e9ecf-0658-4e6d-be15-aed893865905', 'source_file': 'Protocolo_v1_images.md'}\\n\", \"{'Figure/Table/SupplementaryTable': 'Figure 3', 'Section': '4 Diagnosis', 'Subsection': '4.9 Echocardiography', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': 'd27c4071-516e-4610-af7a-d2365e681201', 'source_file': 'Protocolo_v1_images.md'}\\n\", \"{'Figure/Table/SupplementaryTable': 'Figure 6', 'References': 'Figure 3', 'Section': '7 Integrated risk-adapted diagnosis and management', 'Subsection': '7.2.3 Management of low-risk pulmonary embolism: triage for early discharge and home treatment', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': 'b5a6f503-93b1-4ff3-9f9f-872a60d9d75e', 'source_file': 'Protocolo_v1_images.md'}\\n\"]\n",
      "Retrieved information: [Document(id='2bf89016-5515-4b96-9e26-dc61e3c37a2a', metadata={'Figure/Table/SupplementaryTable': 'Table 8', 'References': 'Figure 3', 'Section': '5 Assessment of pulmonary embolism severity and the risk of early death', 'Subsection': '5.6 Prognostic assessment strategy', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '2bf89016-5515-4b96-9e26-dc61e3c37a2a', 'source_file': 'Protocolo_v1_images.md'}, page_content='Table 8: Classification of pulmonary embolism severity and the **risk** of early (in-hospital or 30 day) death\\n| Early mortality risk   | Haemodynamic instabilitya   | Clinical parameters of PE severity and/or comorbidity: PESI class III - V or sPESI 1  | RV dysfunction on TTE or CTPA (b) | Elevated cardiac troponin levelsc |\\n|------------------------|-----------------------------|----------------------------------------------------------------------------------------|-----------------------------------|-----------------------------------|\\n| High                   | +                           | + (d)                                                                                  | +                                 | +                                 |\\n| Intermediate-high      | -                           | + (e)                                                                                  | +                                 | +                                 |\\n| Intermediate-low       | -                           | + (e)                                                                                  | One (or none) positive            | One (or none) positive            |\\n| Low                    | -                           | -                                                                                      | -                                 | -                                 |  \\nBP = blood pressure; CTPA = computed tomography pulmonary angiography; H-FABP = heart-type fatty acid-binding protein; NT-proBNP = N-terminal pro B-type natriuretic peptide; PE = pulmonary embolism; PESI = Pulmonary Embolism Severity Index; RV = right ventricular; sPESI = simplified Pulmonary Embolism Severity Index; TTE = transthoracic echocardiogram.  \\n$^{a}$ One of the following clinical presentations ( Table 4 ): cardiac arrest, obstructive shock (systolic BP <90 mmHg or vasopressors required to achieve a BP >\\\\_90 mmHg despite an adequate filling status, in combination with end-organ hypoperfusion), or persistent hypotension (systolic BP <90 mmHg or a systolic BP drop >\\\\_40 mmHg for >15 min, not caused by new-onset arrhythmia, hypovolaemia, or sepsis).  \\n$^{b}$ Prognostically relevant imaging (TTE or CTPA) findings in patients with acute PE, and the corresponding cut-off levels, are graphically presented in Figure 3 , and their prognostic value is summarized in Supplementary Data Table 3 .  \\n$^{c}$ Elevation of further laboratory biomarkers, such as NT-proBNP >\\\\_600 ng/L, H-FABP >\\\\_6 ng/mL, or copeptin >\\\\_24 pmol/L, may provide additional prognostic information. These markers have been validated in cohort studies but they have not yet been used to guide treatment decisions in randomized controlled trials.  \\n$^{d}$ Haemodynamic instability, combined with PE confirmation on CTPA and/or evidence of RV dysfunction on TTE, is sufficient to classify a patient into the high-risk PE category. In these cases, neither calculation of the PESI nor measurement of troponins or other cardiac biomarkers is necessary.  \\n$^{e}$ Signs of RV dysfunction on TTE (or CTPA) or elevated cardiac biomarker levels may be present, despite a calculated PESI of I - II or an sPESI of 0. 234 Until the implications of such discrepancies for the management of PE are fully understood, these patients should be classified into the intermediate-risk category.'), Document(id='03f717c9-1f3f-4086-94b9-e753fbbe20a9', metadata={'References': 'Table 8, section 7, Figure 6', 'Section': '5 Assessment of pulmonary embolism severity and the risk of early death', 'Subsection': '5.6 Prognostic assessment strategy', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '03f717c9-1f3f-4086-94b9-e753fbbe20a9', 'source_file': 'Protocolo_v1_images.md'}, page_content=\"The classification of PE severity and the risk of early (in-hospital or 30 day) death is summarized in Table 8 . Risk assessment of acute PE begins upon suspicion of the disease and initiation of the diagnostic workup. At this early stage, it is critical to identify patients with (suspected) high-risk PE. This clinical setting necessitates an emergency diagnostic algorithm ( Figure 4 ) and immediate referral for reperfusion treatment, as explained in section 7 , and displayed in Figure 6 and Supplementary Data Figure 1 . Testing for laboratory biomarkers such as cardiac troponins or natriuretic peptides is not necessary for immediate therapeutic decisions in patients with high-risk PE.  \\nIn the absence of haemodynamic instability at presentation, further risk stratification of PE is recommended, as it has implications for early discharge vs. hospitalization or monitoring of the patient (explained in section 7 ). Table 8 provides an overview of the clinical, imaging, and laboratory parameters used to distinguish intermediateand low-risk PE. The PESI is-in its original or simplified form-the most extensively validated and most broadly used clinical score to date, as it integrates baseline indicators of the severity of the acute PE episode with aggravating conditions and the comorbidity of the patient. Overall, a PESI of class I - II or an sPESI of 0 is a reliable predictor of low-risk PE.  \\nIn addition to clinical parameters, patients in the intermediate-risk group who display evidence of both RV dysfunction (on echocardiography or CTPA) and elevated cardiac biomarker levels in the circulation (particularly a positive cardiac troponin test) are classified into the intermediate-high-risk category. As will be discussed in more detail in section 7 , close monitoring is recommended in these cases to permit the early detection of haemodynamic decompensation or collapse, and consequently the need for rescue reperfusion therapy. 179 Patients in whom the RV appears normal on echocardiography or CTPA, and/or who have normal cardiac biomarker levels, belong to the intermediate-low-risk category. As an alternative approach, use of further prognostic scores combining clinical, imaging, and laboratory parameters may be considered to semi-quantitatively assess the severity of the PE episode, and distinguish intermediate-high-risk and intermediate-low-risk PE. Supplementary Data Table 4 lists the scores most frequently investigated for this purpose in observational (cohort) studies; however, none of them has been used in RCTs to date.  \\nA recent meta-analysis included 21 cohort studies with a total of 3295 patients with 'low-risk' PE based on a PESI of I - II or an sPESI of 0. 234 Overall, 34% (95% CI 30 - 39%) of them were reported to have signs of RV dysfunction on echocardiography or CTPA. Data on early mortality were provided in seven studies (1597 patients) and revealed an OR of 4.19 (95% CI 1.39 - 12.58) for death from any cause in the presence of RV dysfunction; elevated cardiac troponin levels were associated with a comparable magnitude of risk elevation. 234 Early all-cause mortality rates (1.8% for RV dysfunction and 3.8% for elevated troponin levels) were in the lower range of those previously reported for patients with intermediate-risk PE. 235 Until the clinical implications of such discrepancies are clarified, patients with signs of RV dysfunction or elevated cardiac biomarkers, despite a low PESI or an sPESI of 0, should be classified into the intermediate-low-risk category.\"), Document(id='8e9e9ecf-0658-4e6d-be15-aed893865905', metadata={'Section': '5 Assessment of pulmonary embolism severity and the risk of early death', 'Subsection': '5.5 Integration of aggravating conditions and comorbidity into risk assessment of acute pulmonary embolism', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '8e9e9ecf-0658-4e6d-be15-aed893865905', 'source_file': 'Protocolo_v1_images.md'}, page_content=\"In addition to the clinical, imaging, and laboratory findings, which are directly linked to PE severity and PE-related early death, baseline parameters related to aggravating conditions and comorbidity are necessary to assess a patient's overall mortality risk and early outcome. Of the clinical scores integrating PE severity and comorbidity, the Pulmonary Embolism Severity Index (PESI) ( Table 7 ) is the one that has been most extensively validated to date. The principal strength of the PESI lies in the reliable identification of patients at low risk for 30 day mortality (PESI classes I and II). One randomized trial employed a low PESI as the principal inclusion criterion for home treatment of acute PE. 178  \\nIn view of the complexity of the original PESI, which includes differently weighed variables, a simplified version (sPESI; Table 7) has been developed and validated. As with the original version of the PESI, the strength of the sPESI lies in the reliable identification of patients at low risk for 30 day mortality. The prognostic performance of the sPESI has been confirmed in observational cohort studies, although this index has not yet been prospectively used to guide therapeutic management of low-risk PE patients.  \\nThe diagnosis of concomitant DVT has been identified as an adverse prognostic factor, being independently associated with death within the first 3 months after acute PE. In a meta-analysis investigating 8859 patients with PE, the presence of concomitant DVT was confirmed as a predictor of 30 day all-cause mortality (OR 1.9, 95% CI 1.5 - 2.4), although it did not predict PE-related adverse outcomes at 90 days. Thus, concomitant DVT can be regarded as an indicator of significant comorbidity in acute PE.\"), Document(id='d27c4071-516e-4610-af7a-d2365e681201', metadata={'Figure/Table/SupplementaryTable': 'Figure 3', 'Section': '4 Diagnosis', 'Subsection': '4.9 Echocardiography', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': 'd27c4071-516e-4610-af7a-d2365e681201', 'source_file': 'Protocolo_v1_images.md'}, page_content=\"Figure 3: Graphic representation of transthoracic echocardiographic parameters in the assessment of right ventricular pressure overload. A 0 =peaklate diastolic (during atrial contraction) velocity of tricuspid annulus by tissue Doppler imaging; AcT = right ventricular outflow Doppler acceleration time; Ao = aorta; E 0 = peak early diastolic velocity of tricuspid annulus by tissue Doppler imaging; IVC = inferior vena cava; LA = left atrium; LV = left ventricle; RA = right atrium; RiHTh = right heart thrombus (or thrombi); RV = right ventricle/ventricular; S 0 = peak systolic velocity of tricuspid annulus by tissue Doppler imaging; TAPSE = tricuspid annular plane systolic excursion; TRPG = tricuspid valve peak systolic gradient.\\nCan be resumed in:\\nA. Enlarged right ventricle, parasternal long axis view\\nB. Dilated RV with basal RV/LV ratio >1.0, and McConnell sign (arrow), four chamber view\\nC. Flattened intraventricular septum (arrows), parasternal short axis view\\nD. Distended inferior vena cava with diminished inspiratory collapsibility, subcostal view\\nE. 60/60 sign: coexistence of acceleration time of pulmonary ejection <60 ms and midsystolic notch with mildly elevated (<60 mmHg) peak systolic gradient at the tricuspid valve\\nF. Right heart mobile thrombus detected in right heart cavities (arrow)\\nG. Decreased tricuspid annular plane systolic excursion (TAPSE) measured with M-Mode (<16 mm)\\nH. Decreased peak systolic (S') velocity of tricuspid annulus (<9.5 cm/s)\"), Document(id='b5a6f503-93b1-4ff3-9f9f-872a60d9d75e', metadata={'Figure/Table/SupplementaryTable': 'Figure 6', 'References': 'Figure 3', 'Section': '7 Integrated risk-adapted diagnosis and management', 'Subsection': '7.2.3 Management of low-risk pulmonary embolism: triage for early discharge and home treatment', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': 'b5a6f503-93b1-4ff3-9f9f-872a60d9d75e', 'source_file': 'Protocolo_v1_images.md'}, page_content='Figure 6: DIAGNOSTIC ALGORITHM FOR PATIENTS WITH SUSPECTED PULMONARY EMBOLISM WITHOUT HAEMODYNAMIC INSTBILITY\\n<!-- image resumen-->\\n1. Initial steps:\\n- Patient with acute PE:\\n- **Anticoagulate**.\\n- **Haemodynamic instability**:\\n- **Yes (High Risk)**: Refer to emergency management algorithm. Consider:\\n- Reperfusion treatment.\\n- Haemodynamic support.\\n- **No**: Distinguish between low and intermediate-risk PE.  \\nRisk assessment:\\n1. **Check clinical signs of PE severity or serious comorbidity**:\\n- PESI class III-IV or sPESI >0.\\n- Alternatively, >0 Hestia criterion (refer to Supplementary Data Table 12).\\n2. **Check for RV dysfunction on TTE or CTPA**:\\n- Prognostically relevant imaging findings are shown in Figure 3.  \\nRisk classification:\\n- **Neither 1 nor 2 present**:\\n- **Low Risk**:\\n- Discharge early with home treatment if:\\n- No other reasons for hospitalization.\\n- Family or social support available.\\n- Easy access to medical care.\\n- **1 or 2 present**:\\n- Perform **troponin test**:\\n- **Troponin negative**:\\n- **Intermediate-Low Risk**: Hospitalize.\\n- **Troponin positive + RV dysfunction**:\\n- **Intermediate-High Risk**: Monitor and consider rescue reperfusion if deterioration occurs.\\n<!-- image resumen-->\\nCTPA = computed tomography pulmonary angiography/angiogram; PE = pulmonary embolism; PESI = Pulmonary Embolism Severity Index; RV = right ventricular; sPESI = simplified Pulmonary Embolism Severity Index; TTE = transthoracic echocardiogram.  \\n- $^{a}$ See also emergency management algorithm shown in the online Supplementary Data.\\n- $^{b}$ Refer to Table 8 for definition of high, intermediate-high-, intermediate-low-, and low-risk PE.\\n- $^{c}$ Cancer, heart failure and chronic lung disease are included in the PESI and sPESI ( Table 7 ).\\n- $^{d}$ See Supplementary Data Table 12 for the Hestia criteria.\\n- $^{e}$ Prognostically relevant imaging (TTE or CTPA) findings in patients with acute PE, are graphically presented in Figure 3 .\\n- $^{f}$ A cardiac troponin test may already have been performed during initial diagnostic work-up.\\n- $^{g}$ Included in the Hestia criteria.')]\n",
      "\n",
      "####################################################\n",
      "######## CURRENT NODE: QUERY SOLVER NODE ###########\n",
      "####################################################\n",
      "\n",
      "##### Processed Retrieval Queries #####\n",
      "['risk assessment early mortality pulmonary embolism']\n",
      "\n",
      "### LLM Response: content='' additional_kwargs={'tool_calls': [{'id': 'call_N7RD203iJ0X8xALSTsboJEsH', 'function': {'arguments': '{\"query\":\"risk assessment early mortality pulmonary embolism calculation methods\",\"top_k\":3,\"reranking\":true,\"top_k_rerank\":2,\"include_refs\":true}', 'name': 'retrieval_tool'}, 'type': 'function'}], 'refusal': None} response_metadata={'token_usage': {'completion_tokens': 47, 'prompt_tokens': 4282, 'total_tokens': 4329, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4.1-mini-2025-04-14', 'system_fingerprint': 'fp_6f2eabb9a5', 'id': 'chatcmpl-BrJu4rQmMjLBH74qgnJZtjVdgI7Bj', 'finish_reason': 'tool_calls', 'logprobs': None} id='run--72d47195-90a2-447b-a11c-bc74678c2858-0' tool_calls=[{'name': 'retrieval_tool', 'args': {'query': 'risk assessment early mortality pulmonary embolism calculation methods', 'top_k': 3, 'reranking': True, 'top_k_rerank': 2, 'include_refs': True}, 'id': 'call_N7RD203iJ0X8xALSTsboJEsH', 'type': 'tool_call'}] usage_metadata={'input_tokens': 4282, 'output_tokens': 47, 'total_tokens': 4329, 'input_token_details': {'audio': 0, 'cache_read': 0}, 'output_token_details': {'audio': 0, 'reasoning': 0}} ###\n",
      "\n",
      "ACTIVATING RETRIEVAL TOOL\n",
      "\n",
      "######################################################\n",
      "######## CURRENT NODE: RETRIEVAL TOOL NODE #############\n",
      "########################################################\n",
      "\n",
      "Retrieval Tool Invoked with the following parameters:\n",
      "\n",
      "Query: risk assessment early mortality pulmonary embolism calculation methods\n",
      "\n",
      "Top K: 3\n",
      "\n",
      "Reranking: True\n",
      "\n",
      "Top K Rerank: 2\n",
      "\n",
      "Include References: True\n",
      "\n",
      "##### Retrieved Documents #####\n",
      "[\"{'References': 'Table 8, section 7, Figure 6', 'Section': '5 Assessment of pulmonary embolism severity and the risk of early death', 'Subsection': '5.6 Prognostic assessment strategy', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '03f717c9-1f3f-4086-94b9-e753fbbe20a9', 'source_file': 'Protocolo_v1_images.md'}\\n\", \"{'Section': '5 Assessment of pulmonary embolism severity and the risk of early death', 'Subsection': '5.5 Integration of aggravating conditions and comorbidity into risk assessment of acute pulmonary embolism', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '8e9e9ecf-0658-4e6d-be15-aed893865905', 'source_file': 'Protocolo_v1_images.md'}\\n\", \"{'Figure/Table/SupplementaryTable': 'Table 8', 'References': 'Figure 3', 'Section': '5 Assessment of pulmonary embolism severity and the risk of early death', 'Subsection': '5.6 Prognostic assessment strategy', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '2bf89016-5515-4b96-9e26-dc61e3c37a2a', 'source_file': 'Protocolo_v1_images.md'}\\n\", \"{'Figure/Table/SupplementaryTable': 'Figure 6', 'References': 'Figure 3', 'Section': '7 Integrated risk-adapted diagnosis and management', 'Subsection': '7.2.3 Management of low-risk pulmonary embolism: triage for early discharge and home treatment', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': 'b5a6f503-93b1-4ff3-9f9f-872a60d9d75e', 'source_file': 'Protocolo_v1_images.md'}\\n\"]\n",
      "\n",
      "Tool call response: \n",
      "Retrieved Docs in tool: [\"{'References': 'Table 8, section 7, Figure 6', 'Section': '5 Assessment of pulmonary embolism severity and the risk of early death', 'Subsection': '5.6 Prognostic assessment strategy', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '03f717c9-1f3f-4086-94b9-e753fbbe20a9', 'source_file': 'Protocolo_v1_images.md'}\\n\", \"{'Section': '5 Assessment of pulmonary embolism severity and the risk of early death', 'Subsection': '5.5 Integration of aggravating conditions and comorbidity into risk assessment of acute pulmonary embolism', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '8e9e9ecf-0658-4e6d-be15-aed893865905', 'source_file': 'Protocolo_v1_images.md'}\\n\", \"{'Figure/Table/SupplementaryTable': 'Table 8', 'References': 'Figure 3', 'Section': '5 Assessment of pulmonary embolism severity and the risk of early death', 'Subsection': '5.6 Prognostic assessment strategy', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '2bf89016-5515-4b96-9e26-dc61e3c37a2a', 'source_file': 'Protocolo_v1_images.md'}\\n\", \"{'Figure/Table/SupplementaryTable': 'Figure 6', 'References': 'Figure 3', 'Section': '7 Integrated risk-adapted diagnosis and management', 'Subsection': '7.2.3 Management of low-risk pulmonary embolism: triage for early discharge and home treatment', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': 'b5a6f503-93b1-4ff3-9f9f-872a60d9d75e', 'source_file': 'Protocolo_v1_images.md'}\\n\"]\n",
      "Retrieved information: [Document(id='03f717c9-1f3f-4086-94b9-e753fbbe20a9', metadata={'References': 'Table 8, section 7, Figure 6', 'Section': '5 Assessment of pulmonary embolism severity and the risk of early death', 'Subsection': '5.6 Prognostic assessment strategy', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '03f717c9-1f3f-4086-94b9-e753fbbe20a9', 'source_file': 'Protocolo_v1_images.md'}, page_content=\"The classification of PE severity and the risk of early (in-hospital or 30 day) death is summarized in Table 8 . Risk assessment of acute PE begins upon suspicion of the disease and initiation of the diagnostic workup. At this early stage, it is critical to identify patients with (suspected) high-risk PE. This clinical setting necessitates an emergency diagnostic algorithm ( Figure 4 ) and immediate referral for reperfusion treatment, as explained in section 7 , and displayed in Figure 6 and Supplementary Data Figure 1 . Testing for laboratory biomarkers such as cardiac troponins or natriuretic peptides is not necessary for immediate therapeutic decisions in patients with high-risk PE.  \\nIn the absence of haemodynamic instability at presentation, further risk stratification of PE is recommended, as it has implications for early discharge vs. hospitalization or monitoring of the patient (explained in section 7 ). Table 8 provides an overview of the clinical, imaging, and laboratory parameters used to distinguish intermediateand low-risk PE. The PESI is-in its original or simplified form-the most extensively validated and most broadly used clinical score to date, as it integrates baseline indicators of the severity of the acute PE episode with aggravating conditions and the comorbidity of the patient. Overall, a PESI of class I - II or an sPESI of 0 is a reliable predictor of low-risk PE.  \\nIn addition to clinical parameters, patients in the intermediate-risk group who display evidence of both RV dysfunction (on echocardiography or CTPA) and elevated cardiac biomarker levels in the circulation (particularly a positive cardiac troponin test) are classified into the intermediate-high-risk category. As will be discussed in more detail in section 7 , close monitoring is recommended in these cases to permit the early detection of haemodynamic decompensation or collapse, and consequently the need for rescue reperfusion therapy. 179 Patients in whom the RV appears normal on echocardiography or CTPA, and/or who have normal cardiac biomarker levels, belong to the intermediate-low-risk category. As an alternative approach, use of further prognostic scores combining clinical, imaging, and laboratory parameters may be considered to semi-quantitatively assess the severity of the PE episode, and distinguish intermediate-high-risk and intermediate-low-risk PE. Supplementary Data Table 4 lists the scores most frequently investigated for this purpose in observational (cohort) studies; however, none of them has been used in RCTs to date.  \\nA recent meta-analysis included 21 cohort studies with a total of 3295 patients with 'low-risk' PE based on a PESI of I - II or an sPESI of 0. 234 Overall, 34% (95% CI 30 - 39%) of them were reported to have signs of RV dysfunction on echocardiography or CTPA. Data on early mortality were provided in seven studies (1597 patients) and revealed an OR of 4.19 (95% CI 1.39 - 12.58) for death from any cause in the presence of RV dysfunction; elevated cardiac troponin levels were associated with a comparable magnitude of risk elevation. 234 Early all-cause mortality rates (1.8% for RV dysfunction and 3.8% for elevated troponin levels) were in the lower range of those previously reported for patients with intermediate-risk PE. 235 Until the clinical implications of such discrepancies are clarified, patients with signs of RV dysfunction or elevated cardiac biomarkers, despite a low PESI or an sPESI of 0, should be classified into the intermediate-low-risk category.\"), Document(id='8e9e9ecf-0658-4e6d-be15-aed893865905', metadata={'Section': '5 Assessment of pulmonary embolism severity and the risk of early death', 'Subsection': '5.5 Integration of aggravating conditions and comorbidity into risk assessment of acute pulmonary embolism', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '8e9e9ecf-0658-4e6d-be15-aed893865905', 'source_file': 'Protocolo_v1_images.md'}, page_content=\"In addition to the clinical, imaging, and laboratory findings, which are directly linked to PE severity and PE-related early death, baseline parameters related to aggravating conditions and comorbidity are necessary to assess a patient's overall mortality risk and early outcome. Of the clinical scores integrating PE severity and comorbidity, the Pulmonary Embolism Severity Index (PESI) ( Table 7 ) is the one that has been most extensively validated to date. The principal strength of the PESI lies in the reliable identification of patients at low risk for 30 day mortality (PESI classes I and II). One randomized trial employed a low PESI as the principal inclusion criterion for home treatment of acute PE. 178  \\nIn view of the complexity of the original PESI, which includes differently weighed variables, a simplified version (sPESI; Table 7) has been developed and validated. As with the original version of the PESI, the strength of the sPESI lies in the reliable identification of patients at low risk for 30 day mortality. The prognostic performance of the sPESI has been confirmed in observational cohort studies, although this index has not yet been prospectively used to guide therapeutic management of low-risk PE patients.  \\nThe diagnosis of concomitant DVT has been identified as an adverse prognostic factor, being independently associated with death within the first 3 months after acute PE. In a meta-analysis investigating 8859 patients with PE, the presence of concomitant DVT was confirmed as a predictor of 30 day all-cause mortality (OR 1.9, 95% CI 1.5 - 2.4), although it did not predict PE-related adverse outcomes at 90 days. Thus, concomitant DVT can be regarded as an indicator of significant comorbidity in acute PE.\"), Document(id='2bf89016-5515-4b96-9e26-dc61e3c37a2a', metadata={'Figure/Table/SupplementaryTable': 'Table 8', 'References': 'Figure 3', 'Section': '5 Assessment of pulmonary embolism severity and the risk of early death', 'Subsection': '5.6 Prognostic assessment strategy', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '2bf89016-5515-4b96-9e26-dc61e3c37a2a', 'source_file': 'Protocolo_v1_images.md'}, page_content='Table 8: Classification of pulmonary embolism severity and the **risk** of early (in-hospital or 30 day) death\\n| Early mortality risk   | Haemodynamic instabilitya   | Clinical parameters of PE severity and/or comorbidity: PESI class III - V or sPESI 1  | RV dysfunction on TTE or CTPA (b) | Elevated cardiac troponin levelsc |\\n|------------------------|-----------------------------|----------------------------------------------------------------------------------------|-----------------------------------|-----------------------------------|\\n| High                   | +                           | + (d)                                                                                  | +                                 | +                                 |\\n| Intermediate-high      | -                           | + (e)                                                                                  | +                                 | +                                 |\\n| Intermediate-low       | -                           | + (e)                                                                                  | One (or none) positive            | One (or none) positive            |\\n| Low                    | -                           | -                                                                                      | -                                 | -                                 |  \\nBP = blood pressure; CTPA = computed tomography pulmonary angiography; H-FABP = heart-type fatty acid-binding protein; NT-proBNP = N-terminal pro B-type natriuretic peptide; PE = pulmonary embolism; PESI = Pulmonary Embolism Severity Index; RV = right ventricular; sPESI = simplified Pulmonary Embolism Severity Index; TTE = transthoracic echocardiogram.  \\n$^{a}$ One of the following clinical presentations ( Table 4 ): cardiac arrest, obstructive shock (systolic BP <90 mmHg or vasopressors required to achieve a BP >\\\\_90 mmHg despite an adequate filling status, in combination with end-organ hypoperfusion), or persistent hypotension (systolic BP <90 mmHg or a systolic BP drop >\\\\_40 mmHg for >15 min, not caused by new-onset arrhythmia, hypovolaemia, or sepsis).  \\n$^{b}$ Prognostically relevant imaging (TTE or CTPA) findings in patients with acute PE, and the corresponding cut-off levels, are graphically presented in Figure 3 , and their prognostic value is summarized in Supplementary Data Table 3 .  \\n$^{c}$ Elevation of further laboratory biomarkers, such as NT-proBNP >\\\\_600 ng/L, H-FABP >\\\\_6 ng/mL, or copeptin >\\\\_24 pmol/L, may provide additional prognostic information. These markers have been validated in cohort studies but they have not yet been used to guide treatment decisions in randomized controlled trials.  \\n$^{d}$ Haemodynamic instability, combined with PE confirmation on CTPA and/or evidence of RV dysfunction on TTE, is sufficient to classify a patient into the high-risk PE category. In these cases, neither calculation of the PESI nor measurement of troponins or other cardiac biomarkers is necessary.  \\n$^{e}$ Signs of RV dysfunction on TTE (or CTPA) or elevated cardiac biomarker levels may be present, despite a calculated PESI of I - II or an sPESI of 0. 234 Until the implications of such discrepancies for the management of PE are fully understood, these patients should be classified into the intermediate-risk category.'), Document(id='b5a6f503-93b1-4ff3-9f9f-872a60d9d75e', metadata={'Figure/Table/SupplementaryTable': 'Figure 6', 'References': 'Figure 3', 'Section': '7 Integrated risk-adapted diagnosis and management', 'Subsection': '7.2.3 Management of low-risk pulmonary embolism: triage for early discharge and home treatment', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': 'b5a6f503-93b1-4ff3-9f9f-872a60d9d75e', 'source_file': 'Protocolo_v1_images.md'}, page_content='Figure 6: DIAGNOSTIC ALGORITHM FOR PATIENTS WITH SUSPECTED PULMONARY EMBOLISM WITHOUT HAEMODYNAMIC INSTBILITY\\n<!-- image resumen-->\\n1. Initial steps:\\n- Patient with acute PE:\\n- **Anticoagulate**.\\n- **Haemodynamic instability**:\\n- **Yes (High Risk)**: Refer to emergency management algorithm. Consider:\\n- Reperfusion treatment.\\n- Haemodynamic support.\\n- **No**: Distinguish between low and intermediate-risk PE.  \\nRisk assessment:\\n1. **Check clinical signs of PE severity or serious comorbidity**:\\n- PESI class III-IV or sPESI >0.\\n- Alternatively, >0 Hestia criterion (refer to Supplementary Data Table 12).\\n2. **Check for RV dysfunction on TTE or CTPA**:\\n- Prognostically relevant imaging findings are shown in Figure 3.  \\nRisk classification:\\n- **Neither 1 nor 2 present**:\\n- **Low Risk**:\\n- Discharge early with home treatment if:\\n- No other reasons for hospitalization.\\n- Family or social support available.\\n- Easy access to medical care.\\n- **1 or 2 present**:\\n- Perform **troponin test**:\\n- **Troponin negative**:\\n- **Intermediate-Low Risk**: Hospitalize.\\n- **Troponin positive + RV dysfunction**:\\n- **Intermediate-High Risk**: Monitor and consider rescue reperfusion if deterioration occurs.\\n<!-- image resumen-->\\nCTPA = computed tomography pulmonary angiography/angiogram; PE = pulmonary embolism; PESI = Pulmonary Embolism Severity Index; RV = right ventricular; sPESI = simplified Pulmonary Embolism Severity Index; TTE = transthoracic echocardiogram.  \\n- $^{a}$ See also emergency management algorithm shown in the online Supplementary Data.\\n- $^{b}$ Refer to Table 8 for definition of high, intermediate-high-, intermediate-low-, and low-risk PE.\\n- $^{c}$ Cancer, heart failure and chronic lung disease are included in the PESI and sPESI ( Table 7 ).\\n- $^{d}$ See Supplementary Data Table 12 for the Hestia criteria.\\n- $^{e}$ Prognostically relevant imaging (TTE or CTPA) findings in patients with acute PE, are graphically presented in Figure 3 .\\n- $^{f}$ A cardiac troponin test may already have been performed during initial diagnostic work-up.\\n- $^{g}$ Included in the Hestia criteria.')]\n",
      "\n",
      "####################################################\n",
      "######## CURRENT NODE: QUERY SOLVER NODE ###########\n",
      "####################################################\n",
      "\n",
      "##### Processed Retrieval Queries #####\n",
      "['risk assessment early mortality pulmonary embolism', 'risk assessment early mortality pulmonary embolism calculation methods']\n",
      "\n",
      "### LLM Response: content='The risk of early mortality in a patient with acute pulmonary embolism (PE) is calculated through a structured risk stratification approach that integrates clinical, imaging, and laboratory parameters as follows:\\n\\n1. Identify High-Risk PE:\\n   - Presence of haemodynamic instability (cardiac arrest, obstructive shock, or persistent hypotension) classifies the patient as high risk.\\n   - In this group, immediate reperfusion treatment is indicated, and further risk scores or biomarker testing are not required for initial decision-making.\\n\\n2. In the absence of haemodynamic instability, further risk stratification is performed using:\\n   - Clinical severity and comorbidity assessment via the Pulmonary Embolism Severity Index (PESI) or its simplified version (sPESI).\\n     - PESI class III-V or sPESI 1 indicates increased risk.\\n     - PESI class I-II or sPESI = 0 indicates low risk.\\n   - Imaging evidence of right ventricular (RV) dysfunction on transthoracic echocardiography (TTE) or computed tomography pulmonary angiography (CTPA).\\n   - Elevated cardiac biomarkers, particularly cardiac troponins.\\n\\n3. Risk Categories Based on Combined Parameters (Table 8):\\n   - High Risk: Haemodynamic instability + clinical severity + RV dysfunction + elevated troponins.\\n   - Intermediate-High Risk: No haemodynamic instability, but clinical severity + RV dysfunction + elevated troponins.\\n   - Intermediate-Low Risk: No haemodynamic instability, clinical severity present, and one or none of RV dysfunction or elevated troponins.\\n   - Low Risk: No haemodynamic instability, no clinical severity (PESI I-II or sPESI 0), no RV dysfunction, and no elevated troponins.\\n\\n4. Additional Considerations:\\n   - The presence of concomitant deep vein thrombosis (DVT) is an adverse prognostic factor and may increase mortality risk.\\n   - Other biomarkers such as NT-proBNP, H-FABP, or copeptin may provide additional prognostic information but are not yet standard for guiding treatment.\\n   - Patients with low PESI or sPESI but with RV dysfunction or elevated biomarkers should be classified as intermediate risk and monitored closely.\\n\\n5. Diagnostic Algorithm Summary:\\n   - Start anticoagulation immediately.\\n   - Assess haemodynamic status.\\n   - If stable, assess clinical severity (PESI/sPESI), RV function (TTE/CTPA), and troponin levels.\\n   - Use these parameters to classify risk and guide management decisions including hospitalization, monitoring, or early discharge.\\n\\nIn summary, the calculation of early mortality risk in PE patients relies primarily on haemodynamic status, clinical severity scores (PESI/sPESI), imaging evidence of RV dysfunction, and cardiac biomarker elevation. This integrated approach allows classification into high, intermediate-high, intermediate-low, or low risk, which guides clinical management and prognosis.' additional_kwargs={'refusal': None} response_metadata={'token_usage': {'completion_tokens': 601, 'prompt_tokens': 6659, 'total_tokens': 7260, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 3200}}, 'model_name': 'gpt-4.1-mini-2025-04-14', 'system_fingerprint': 'fp_6f2eabb9a5', 'id': 'chatcmpl-BrJuANOvrQUvUcbCOnvkuDwe3Zj9a', 'finish_reason': 'stop', 'logprobs': None} id='run--cf039999-0b6d-462c-a8a2-170f58cd866c-0' usage_metadata={'input_tokens': 6659, 'output_tokens': 601, 'total_tokens': 7260, 'input_token_details': {'audio': 0, 'cache_read': 3200}, 'output_token_details': {'audio': 0, 'reasoning': 0}} ###\n",
      "The answer to the user query: How to calculate the risk of early mortality of a TPE patient is:\n",
      " The risk of early mortality in a patient with acute pulmonary embolism (PE) is calculated through a structured risk stratification approach that integrates clinical, imaging, and laboratory parameters as follows:\n",
      "\n",
      "1. Identify High-Risk PE:\n",
      "   - Presence of haemodynamic instability (cardiac arrest, obstructive shock, or persistent hypotension) classifies the patient as high risk.\n",
      "   - In this group, immediate reperfusion treatment is indicated, and further risk scores or biomarker testing are not required for initial decision-making.\n",
      "\n",
      "2. In the absence of haemodynamic instability, further risk stratification is performed using:\n",
      "   - Clinical severity and comorbidity assessment via the Pulmonary Embolism Severity Index (PESI) or its simplified version (sPESI).\n",
      "     - PESI class III-V or sPESI 1 indicates increased risk.\n",
      "     - PESI class I-II or sPESI = 0 indicates low risk.\n",
      "   - Imaging evidence of right ventricular (RV) dysfunction on transthoracic echocardiography (TTE) or computed tomography pulmonary angiography (CTPA).\n",
      "   - Elevated cardiac biomarkers, particularly cardiac troponins.\n",
      "\n",
      "3. Risk Categories Based on Combined Parameters (Table 8):\n",
      "   - High Risk: Haemodynamic instability + clinical severity + RV dysfunction + elevated troponins.\n",
      "   - Intermediate-High Risk: No haemodynamic instability, but clinical severity + RV dysfunction + elevated troponins.\n",
      "   - Intermediate-Low Risk: No haemodynamic instability, clinical severity present, and one or none of RV dysfunction or elevated troponins.\n",
      "   - Low Risk: No haemodynamic instability, no clinical severity (PESI I-II or sPESI 0), no RV dysfunction, and no elevated troponins.\n",
      "\n",
      "4. Additional Considerations:\n",
      "   - The presence of concomitant deep vein thrombosis (DVT) is an adverse prognostic factor and may increase mortality risk.\n",
      "   - Other biomarkers such as NT-proBNP, H-FABP, or copeptin may provide additional prognostic information but are not yet standard for guiding treatment.\n",
      "   - Patients with low PESI or sPESI but with RV dysfunction or elevated biomarkers should be classified as intermediate risk and monitored closely.\n",
      "\n",
      "5. Diagnostic Algorithm Summary:\n",
      "   - Start anticoagulation immediately.\n",
      "   - Assess haemodynamic status.\n",
      "   - If stable, assess clinical severity (PESI/sPESI), RV function (TTE/CTPA), and troponin levels.\n",
      "   - Use these parameters to classify risk and guide management decisions including hospitalization, monitoring, or early discharge.\n",
      "\n",
      "In summary, the calculation of early mortality risk in PE patients relies primarily on haemodynamic status, clinical severity scores (PESI/sPESI), imaging evidence of RV dysfunction, and cardiac biomarker elevation. This integrated approach allows classification into high, intermediate-high, intermediate-low, or low risk, which guides clinical management and prognosis.\n",
      "\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|| 1/1 [00:11<00:00, 11.84s/it]\n",
      "100%|| 8/8 [00:11<00:00,  1.40s/it]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "###### Detected Hallucinations: ######\n",
      "\n",
      "[]\n",
      "\n",
      "THE ANSWER WAS GENERATED\n",
      "\n",
      "######################################################\n",
      "######## CURRENT NODE: QUERY INPUT NODE ##############\n",
      "######################################################\n",
      "\n",
      "Please type your query, or write 'Goodbye' if you want to end the session:\n",
      "\n",
      "###############################################\n",
      "####### CURRENT NODE: ORCHESTRATOR NODE #######\n",
      "###############################################\n",
      "\n",
      "### User Query Detected: Bye ###\n",
      "### LLM Response: finish session request ###\n",
      "### Next Action Decided: finish session request ###\n",
      "\n",
      "########################################################\n",
      "######## CURRENT NODE: FINISH SESSION NODE #############\n",
      "########################################################\n",
      "\n",
      "Session Finished. Thank you for using the system!\n",
      "Session Finished.\n"
     ]
    }
   ],
   "source": [
    "# Specify an ID for the thread\n",
    "config = {\"configurable\": {\"thread_id\": \"ab2\"}, \"recursion_limit\": 100}\n",
    "\n",
    "state = CustomState(\n",
    "    external_messages=[AIMessage(content=\"Welcome! How can I assist you today?\")],\n",
    "    messages=[SystemMessage(content=\"Excel path: data/clinical_cases/clinical_cases.xlsx\")],\n",
    "    patient_data={},\n",
    "    metrics={},\n",
    "    clinical_case_evaluation_reports=[],\n",
    "    guidelines_consultation_responses=[],\n",
    "    retrieved_information=[],\n",
    "    retrieval_queries=[],\n",
    "    finish=False,\n",
    "    prepare_final_message=False,\n",
    ")\n",
    "\n",
    "# Initialize the streaming process\n",
    "stream = graph.stream(state, config=config, stream_mode=\"values\")\n",
    "\n",
    "finish = False\n",
    "# Iterate through the events\n",
    "while not finish:\n",
    "    try:\n",
    "        event = next(stream)\n",
    "\n",
    "        if event[\"finish\"]:\n",
    "            print(\"Session Finished.\")\n",
    "            finish = True\n",
    "    \n",
    "    except Exception as e:\n",
    "        print(f\"Error: {e}\")\n",
    "        break\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Display Results"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Messages"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### External Messages"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "\n",
      "Welcome! How can I assist you today?\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "\n",
      "Please type your query:\n",
      "================================\u001b[1m Human Message \u001b[0m=================================\n",
      "\n",
      "Which scores can we find in the guidelines to evaluate the risk of the PE on a patient?\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "\n",
      "The guidelines present two main clinical prediction rules to evaluate the risk of pulmonary embolism (PE) in patients: the revised Geneva score and the Wells score. Both scores combine clinical symptoms, signs, and predisposing factors to classify patients into categories of clinical or pre-test probability of PE.\n",
      "\n",
      "1. Revised Geneva Score:\n",
      "- It includes items such as previous PE or deep vein thrombosis (DVT), heart rate ranges, recent surgery or fracture, hemoptysis, active cancer, unilateral lower-limb pain, signs of deep venous thrombosis, and age over 65 years.\n",
      "- The score can be used in a three-level classification (low, intermediate, high probability) or a two-level classification (PE-unlikely, PE-likely).\n",
      "- Simplified versions of the score exist to facilitate clinical use.\n",
      "- The approximate prevalence of confirmed PE is about 10% in low probability, 30% in intermediate, and 65% in high probability categories.\n",
      "\n",
      "2. Wells Score:\n",
      "- It includes previous PE or DVT, heart rate >100 bpm, recent surgery or immobilization, hemoptysis, active cancer, clinical signs of DVT, and whether an alternative diagnosis is less likely than PE.\n",
      "- The Wells score also has an original and a simplified version.\n",
      "- It can be applied as a three-level score (low, intermediate, high probability) or a two-level score (PE unlikely, PE likely).\n",
      "- The simplified version mainly uses a two-level classification.\n",
      "\n",
      "Both scores have been externally validated and show similar diagnostic performance. They are essential in the diagnostic algorithm for PE because the post-test probability after imaging depends on the pre-test probability assessed by these scores or clinical judgment.\n",
      "\n",
      "In summary, the guidelines recommend using the revised Geneva score and the Wells score, both available in original and simplified forms, to stratify patients suspected of PE into risk categories that guide further diagnostic and management steps.\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "\n",
      "Please type your query:\n",
      "================================\u001b[1m Human Message \u001b[0m=================================\n",
      "\n",
      "Bye\n"
     ]
    }
   ],
   "source": [
    "chat_history = event[\"external_messages\"]\n",
    "for message in chat_history:\n",
    "    message.pretty_print()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Internal Messages"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "================================\u001b[1m System Message \u001b[0m================================\n",
      "\n",
      "Excel path: data/clinical_cases/clinical_cases.xlsx\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "\n",
      "Patient data for Patient ID Patient 1 successfully loaded.\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "\n",
      "Please type your query, or write 'Goodbye' if you want to end the session:\n",
      "================================\u001b[1m Human Message \u001b[0m=================================\n",
      "\n",
      "Which scores can we find in the guidelines to evaluate the risk of the PE on a patient?\n",
      "================================\u001b[1m System Message \u001b[0m================================\n",
      "\n",
      "Planner decided next action: guidelines consultation request based on user query: \"Which scores can we find in the guidelines to evaluate the risk of the PE on a patient?\".\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "\n",
      "guidelines consultation request\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "Tool Calls:\n",
      "  retrieval_tool (call_yYZcfNsgbWNhzQVHDKPneyyn)\n",
      " Call ID: call_yYZcfNsgbWNhzQVHDKPneyyn\n",
      "  Args:\n",
      "    query: risk scores for pulmonary embolism evaluation\n",
      "    top_k: 5\n",
      "    reranking: True\n",
      "    top_k_rerank: 3\n",
      "    include_refs: True\n",
      "=================================\u001b[1m Tool Message \u001b[0m=================================\n",
      "\n",
      "[\"page_content='The combination of symptoms and clinical findings with the presence of predisposing factors for VTE allows the classification of patients with suspected PE into distinct categories of clinical or pre-test probability, which correspond to an increasing actual prevalence of confirmed PE. This pre-test assessment can be done either by implicit (empirical) clinical judgement or by using prediction rules. As the post-test (i.e. after an imaging test) probability of PE depends not only on the characteristics of the diagnostic test itself but also on the pretest probability, this is a key step in all diagnostic algorithms for PE.  \\nThe value of empirical clinical judgement has been confirmed in several large series. Clinical judgement usually includes commonplace tests such as chest X-rays and electrocardiograms for differential diagnosis. However, as clinical judgement lacks standardization, several explicit clinical prediction rules have been developed. Of these, the most frequently used prediction rules are the revised Geneva rule ( Table 5 ) and the Wells rule (see Supplementary Data Table 1). Both prediction rules have been simplified in an attempt to increase their adoption into clinical practice; the simplified versions have been externally validated.  \\nRegardless of the score used, the proportion of patients with confirmed PE can be expected to be ~ 10% in the low-probability category, 30% in the moderate-probability category, and 65% in the highprobability category. When the two-level classification is used, the proportion of patients with confirmed PE is ~ 12% in the PE-unlikely category and 30% in the PE-likely category. A direct prospective comparison of these rules confirmed a similar diagnostic performance.' metadata={'Section': '4 Diagnosis', 'Subsection': '4.2 Assessment of clinical (pre-test) probability', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '7e8aa6cf-f5ad-4ce0-bd85-166634be8a04', 'source_file': 'Protocolo_v1_images.md'}\", \"page_content='Table 5: The revised Geneva clinical prediction rule for pulmonary embolism\\n| Items                                                          | Clinical decision rule points | Simplified Version |\\n|----------------------------------------------------------------|-------------------------------|--------------------|\\n| Previous PE or DVT                                             | 3                             | 1                  |\\n| Heart rate                                                     |                               |                    |\\n|        75 - 94 b.p.m.                                         | 3                             | 1                  |\\n|        > 95 b.p.m.                                            | 5                             | 2                  |\\n| Surgery or fracture within the past month                      | 2                             | 1                  |\\n| Haemoptysis                                                    | 2                             | 1                  |\\n| Active cancer                                                  | 2                             | 1                  |\\n| Unilateral lower-limb pain                                     | 3                             | 1                  |\\n| Pain on lower-limb deep venous palpation and unilateral oedema | 4                             | 1                  |\\n| Age > 65 years                                                 | 1                             | 1                  |  \\n| Clinical probability                                           |                               |                    |\\n|----------------------------------------------------------------|-------------------------------|--------------------|\\n| Three-level score                                              |                               |                    |\\n|        Low                                                    | 0 - 3                         | 0 - 1              |\\n|        Intermediate                                           | 4 - 10                        | 2 - 4              |\\n|        High                                                   | > 11                          | > 5                |\\n| Two-level score                                                |                               |                    |\\n|        PE-unlikely                                            | 0 - 5                         | 0 - 2              |\\n|        PE-likely                                              | > 6                           | > 3                |  \\nb.p.m. = beats per minute; DVT = deep vein thrombosis; PE = pulmonary embolism.' metadata={'Figure/Table/SupplementaryTable': 'Table 5', 'Section': '4 Diagnosis', 'Subsection': '4.1 Clinical presentation', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': 'a992408d-41e8-4c55-a1cc-a91f08191813', 'source_file': 'Protocolo_v1_images.md'}\", \"page_content='Supplementary Table 1: The Wells clinical prediction rule for pulmonary embolism\\n| Items                                             | Clinical decision rule points - Original version                                                  | Simplified version     |\\n|---------------------------------------------------|---------------------------------------------------------------------------------------------------|------------------------|\\n| Previous PE or DVT                                | 1.5                                                                                               | 1                      |\\n| Heart rate >100 b.p.m.                            | 1.5                                                                                               | 1                      |\\n| Surgery or immobilization within the past 4 weeks | 1.5                                                                                               | 1                      |\\n| Haemoptysis                                       | 1                                                                                                 | 1                      |\\n| Active cancer                                     | 1                                                                                                 | 1                      |\\n| Clinical signs of DVT                             | 3                                                                                                 | 1                      |\\n| Alterative diagnosis less likely than PE          | 3                                                                                                 | 1                      |  \\n| Clinical probability                              | Original Version                                                                                  | Simplified version     |\\n|---------------------------------------------------|---------------------------------------------------------------------------------------------------|------------------------|\\n| Three-level score                                 |                                                                                                   |                        |\\n| Low                                               | 0 - 1                                                                                             | N/A                    |\\n| Intermediate                                      | 2 - 6                                                                                             | N/A                    |\\n| High                                              | > \\\\_7                                                                                             | N/A                    |\\n| Two-level score                                   |                                                                                                   |                        |\\n| PE unlikely                                       | 0 - 4                                                                                             | 0 - 1                  |\\n| PE likely                                         | > \\\\_5                                                                                             | > \\\\_2                   |  \\n**Clinical probability**:  \\n- Original Version:\\n1. Three-level score:\\n- Low: 0 - 1\\n- Intermediate: 2 - 6\\n- High: > 6  \\n2. Two-level score:\\n- PE unlikely: 0 - 4\\n- PE likely: > 4  \\n- Simplified version:\\n1. Two-level score:\\n- PE unlikely: 0 - 1\\n- PE likely: > 1  \\nb.p.m. = beats per minute; DVT = deep vein thrombosis; N/A = not applicable; PE = pulmonary embolism.' metadata={'Figure/Table/SupplementaryTable': 'Supplementary Table 1', 'Section': '1 Supplementary Tables and Supplementary Figure', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): supplementary data', 'id': 'f031dec3-ae69-4478-883c-655f38546c82', 'source_file': 'salida_complementary.md'}\"]\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "Tool Calls:\n",
      "  retrieval_tool (call_cuhTgxRt4HJOb3mRdT5qnRi0)\n",
      " Call ID: call_cuhTgxRt4HJOb3mRdT5qnRi0\n",
      "  Args:\n",
      "    query: clinical prediction rules for pulmonary embolism risk assessment\n",
      "    top_k: 3\n",
      "    reranking: True\n",
      "    top_k_rerank: 2\n",
      "    include_refs: True\n",
      "=================================\u001b[1m Tool Message \u001b[0m=================================\n",
      "\n",
      "[\"page_content='The combination of symptoms and clinical findings with the presence of predisposing factors for VTE allows the classification of patients with suspected PE into distinct categories of clinical or pre-test probability, which correspond to an increasing actual prevalence of confirmed PE. This pre-test assessment can be done either by implicit (empirical) clinical judgement or by using prediction rules. As the post-test (i.e. after an imaging test) probability of PE depends not only on the characteristics of the diagnostic test itself but also on the pretest probability, this is a key step in all diagnostic algorithms for PE.  \\nThe value of empirical clinical judgement has been confirmed in several large series. Clinical judgement usually includes commonplace tests such as chest X-rays and electrocardiograms for differential diagnosis. However, as clinical judgement lacks standardization, several explicit clinical prediction rules have been developed. Of these, the most frequently used prediction rules are the revised Geneva rule ( Table 5 ) and the Wells rule (see Supplementary Data Table 1). Both prediction rules have been simplified in an attempt to increase their adoption into clinical practice; the simplified versions have been externally validated.  \\nRegardless of the score used, the proportion of patients with confirmed PE can be expected to be ~ 10% in the low-probability category, 30% in the moderate-probability category, and 65% in the highprobability category. When the two-level classification is used, the proportion of patients with confirmed PE is ~ 12% in the PE-unlikely category and 30% in the PE-likely category. A direct prospective comparison of these rules confirmed a similar diagnostic performance.' metadata={'Section': '4 Diagnosis', 'Subsection': '4.2 Assessment of clinical (pre-test) probability', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '7e8aa6cf-f5ad-4ce0-bd85-166634be8a04', 'source_file': 'Protocolo_v1_images.md'}\", \"page_content='Table 5: The revised Geneva clinical prediction rule for pulmonary embolism\\n| Items                                                          | Clinical decision rule points | Simplified Version |\\n|----------------------------------------------------------------|-------------------------------|--------------------|\\n| Previous PE or DVT                                             | 3                             | 1                  |\\n| Heart rate                                                     |                               |                    |\\n|        75 - 94 b.p.m.                                         | 3                             | 1                  |\\n|        > 95 b.p.m.                                            | 5                             | 2                  |\\n| Surgery or fracture within the past month                      | 2                             | 1                  |\\n| Haemoptysis                                                    | 2                             | 1                  |\\n| Active cancer                                                  | 2                             | 1                  |\\n| Unilateral lower-limb pain                                     | 3                             | 1                  |\\n| Pain on lower-limb deep venous palpation and unilateral oedema | 4                             | 1                  |\\n| Age > 65 years                                                 | 1                             | 1                  |  \\n| Clinical probability                                           |                               |                    |\\n|----------------------------------------------------------------|-------------------------------|--------------------|\\n| Three-level score                                              |                               |                    |\\n|        Low                                                    | 0 - 3                         | 0 - 1              |\\n|        Intermediate                                           | 4 - 10                        | 2 - 4              |\\n|        High                                                   | > 11                          | > 5                |\\n| Two-level score                                                |                               |                    |\\n|        PE-unlikely                                            | 0 - 5                         | 0 - 2              |\\n|        PE-likely                                              | > 6                           | > 3                |  \\nb.p.m. = beats per minute; DVT = deep vein thrombosis; PE = pulmonary embolism.' metadata={'Figure/Table/SupplementaryTable': 'Table 5', 'Section': '4 Diagnosis', 'Subsection': '4.1 Clinical presentation', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': 'a992408d-41e8-4c55-a1cc-a91f08191813', 'source_file': 'Protocolo_v1_images.md'}\"]\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "\n",
      "The guidelines present two main clinical prediction rules to evaluate the risk of pulmonary embolism (PE) in patients: the revised Geneva score and the Wells score. Both scores combine clinical symptoms, signs, and predisposing factors to classify patients into categories of clinical or pre-test probability of PE.\n",
      "\n",
      "1. Revised Geneva Score:\n",
      "- It includes items such as previous PE or deep vein thrombosis (DVT), heart rate ranges, recent surgery or fracture, hemoptysis, active cancer, unilateral lower-limb pain, signs of deep venous thrombosis, and age over 65 years.\n",
      "- The score can be used in a three-level classification (low, intermediate, high probability) or a two-level classification (PE-unlikely, PE-likely).\n",
      "- Simplified versions of the score exist to facilitate clinical use.\n",
      "- The approximate prevalence of confirmed PE is about 10% in low probability, 30% in intermediate, and 65% in high probability categories.\n",
      "\n",
      "2. Wells Score:\n",
      "- It includes previous PE or DVT, heart rate >100 bpm, recent surgery or immobilization, hemoptysis, active cancer, clinical signs of DVT, and whether an alternative diagnosis is less likely than PE.\n",
      "- The Wells score also has an original and a simplified version.\n",
      "- It can be applied as a three-level score (low, intermediate, high probability) or a two-level score (PE unlikely, PE likely).\n",
      "- The simplified version mainly uses a two-level classification.\n",
      "\n",
      "Both scores have been externally validated and show similar diagnostic performance. They are essential in the diagnostic algorithm for PE because the post-test probability after imaging depends on the pre-test probability assessed by these scores or clinical judgment.\n",
      "\n",
      "In summary, the guidelines recommend using the revised Geneva score and the Wells score, both available in original and simplified forms, to stratify patients suspected of PE into risk categories that guide further diagnostic and management steps.\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "\n",
      "The guidelines present two main clinical prediction rules to evaluate the risk of pulmonary embolism (PE) in patients: the revised Geneva score and the Wells score. Both scores combine clinical symptoms, signs, and predisposing factors to classify patients into categories of clinical or pre-test probability of PE.\n",
      "\n",
      "1. Revised Geneva Score:\n",
      "- It includes items such as previous PE or deep vein thrombosis (DVT), heart rate ranges, recent surgery or fracture, hemoptysis, active cancer, unilateral lower-limb pain, signs of deep venous thrombosis, and age over 65 years.\n",
      "- The score can be used in a three-level classification (low, intermediate, high probability) or a two-level classification (PE-unlikely, PE-likely).\n",
      "- Simplified versions of the score exist to facilitate clinical use.\n",
      "- The approximate prevalence of confirmed PE is about 10% in low probability, 30% in intermediate, and 65% in high probability categories.\n",
      "\n",
      "2. Wells Score:\n",
      "- It includes previous PE or DVT, heart rate >100 bpm, recent surgery or immobilization, hemoptysis, active cancer, clinical signs of DVT, and whether an alternative diagnosis is less likely than PE.\n",
      "- The Wells score also has an original and a simplified version.\n",
      "- It can be applied as a three-level score (low, intermediate, high probability) or a two-level score (PE unlikely, PE likely).\n",
      "- The simplified version mainly uses a two-level classification.\n",
      "\n",
      "Both scores have been externally validated and show similar diagnostic performance. They are essential in the diagnostic algorithm for PE because the post-test probability after imaging depends on the pre-test probability assessed by these scores or clinical judgment.\n",
      "\n",
      "In summary, the guidelines recommend using the revised Geneva score and the Wells score, both available in original and simplified forms, to stratify patients suspected of PE into risk categories that guide further diagnostic and management steps.\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "\n",
      "Please type your query, or write 'Goodbye' if you want to end the session:\n",
      "================================\u001b[1m Human Message \u001b[0m=================================\n",
      "\n",
      "Bye\n",
      "================================\u001b[1m System Message \u001b[0m================================\n",
      "\n",
      "Planner decided next action: finish session request based on user query: \"Bye\".\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "\n",
      "finish session request\n",
      "================================\u001b[1m System Message \u001b[0m================================\n",
      "\n",
      "The session has been completed.\n"
     ]
    }
   ],
   "source": [
    "chat_history = event[\"messages\"]\n",
    "for message in chat_history:\n",
    "    message.pretty_print()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Patient Data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'Demographic': {'PATIENT': 1,\n",
       "  'Age': 45,\n",
       "  'Sex': 'female',\n",
       "  'Weight (kg)': 65,\n",
       "  'Height (cm)': 165},\n",
       " 'Patient history': {'Cancer (any type)': 'no',\n",
       "  'Heart failure': 'no',\n",
       "  'COPD': 'no',\n",
       "  'Chronic Cardiopulmonary Disease': 'missing'},\n",
       " 'Absolute Contraindications for ': {'Haemorragic stroke (previous 6 months)': 'no',\n",
       "  'Unknown-origin ischemic stroke (previous 6 months)': 'no',\n",
       "  'Central nervous system neoplasm': 'no',\n",
       "  'Major trauma (previous 3 weeks)': 'no',\n",
       "  'Major surgery (previous 3 weeks)': 'no',\n",
       "  'Bleeding diathesis': 'no',\n",
       "  'Active bleeding': 'missing'},\n",
       " 'Relative Contraindications for ': {'Transient ischemic attack (previous 6 months)': 'no',\n",
       "  'Oral anticoagulation': 'no',\n",
       "  'Pregnancy': 'missing',\n",
       "  'First postpartum week': 'no',\n",
       "  'Non compresible puncture sites': 'no',\n",
       "  'Traumatic resuscitation': 'no',\n",
       "  'Refractory hypertension (SBP>180mmHg)': 'no',\n",
       "  'Advanced liver disease': 'no',\n",
       "  'Infective endocarditis': 'no',\n",
       "  'Active peptic ulcer': 'no'},\n",
       " 'Physical Examination': {'Systolic blood pressure (SBP)': 120,\n",
       "  'Diastolic blood pressure (DBP)': 86,\n",
       "  'Hypoperfusion': 'missing',\n",
       "  'Cardiac frequency': 97,\n",
       "  'Respiratory frequency': 20,\n",
       "  'Temperature (C)': 36.0,\n",
       "  'Altered mental status': 'no',\n",
       "  'Glasgow scale': 15,\n",
       "  'Oxygen saturation (%)': 90},\n",
       " 'Echocardiography': {'RV dysfunction': 'no',\n",
       "  'RV/LV diameter ratio': '<1',\n",
       "  'Tapse': 'Not Available',\n",
       "  'Mcconell_sign': 'Not Available',\n",
       "  'Right heart trombi': 'Not Available',\n",
       "  'IVC diameter (cm)': 'Not Available',\n",
       "  'IVC inspiratory collapsibility': 'Not Available',\n",
       "  'TAPSV': 'Not Available'},\n",
       " 'CTPA': {'Pulmonary embolism': 'yes',\n",
       "  'RV/LV diameter ratio': 'Not Available',\n",
       "  'Contrast reflux int iv': 'Not Available'},\n",
       " 'Laboratory Test': {'Troponin elevated': 'Not Available',\n",
       "  'NtproBNP elevated': 'Not Available',\n",
       "  'Creatinine (mg/dL)': 0.9,\n",
       "  'CrCl (mL/min)': 95}}"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "event['patient_data']"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Retrieved Context"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Retrieval Queries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['risk scores for pulmonary embolism evaluation',\n",
       " 'clinical prediction rules for pulmonary embolism risk assessment']"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "event['retrieval_queries']"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Retrieved Information"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[[Document(id='7e8aa6cf-f5ad-4ce0-bd85-166634be8a04', metadata={'Section': '4 Diagnosis', 'Subsection': '4.2 Assessment of clinical (pre-test) probability', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '7e8aa6cf-f5ad-4ce0-bd85-166634be8a04', 'source_file': 'Protocolo_v1_images.md'}, page_content='The combination of symptoms and clinical findings with the presence of predisposing factors for VTE allows the classification of patients with suspected PE into distinct categories of clinical or pre-test probability, which correspond to an increasing actual prevalence of confirmed PE. This pre-test assessment can be done either by implicit (empirical) clinical judgement or by using prediction rules. As the post-test (i.e. after an imaging test) probability of PE depends not only on the characteristics of the diagnostic test itself but also on the pretest probability, this is a key step in all diagnostic algorithms for PE.  \\nThe value of empirical clinical judgement has been confirmed in several large series. Clinical judgement usually includes commonplace tests such as chest X-rays and electrocardiograms for differential diagnosis. However, as clinical judgement lacks standardization, several explicit clinical prediction rules have been developed. Of these, the most frequently used prediction rules are the revised Geneva rule ( Table 5 ) and the Wells rule (see Supplementary Data Table 1). Both prediction rules have been simplified in an attempt to increase their adoption into clinical practice; the simplified versions have been externally validated.  \\nRegardless of the score used, the proportion of patients with confirmed PE can be expected to be ~ 10% in the low-probability category, 30% in the moderate-probability category, and 65% in the highprobability category. When the two-level classification is used, the proportion of patients with confirmed PE is ~ 12% in the PE-unlikely category and 30% in the PE-likely category. A direct prospective comparison of these rules confirmed a similar diagnostic performance.'),\n",
       "  Document(id='a992408d-41e8-4c55-a1cc-a91f08191813', metadata={'Figure/Table/SupplementaryTable': 'Table 5', 'Section': '4 Diagnosis', 'Subsection': '4.1 Clinical presentation', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': 'a992408d-41e8-4c55-a1cc-a91f08191813', 'source_file': 'Protocolo_v1_images.md'}, page_content='Table 5: The revised Geneva clinical prediction rule for pulmonary embolism\\n| Items                                                          | Clinical decision rule points | Simplified Version |\\n|----------------------------------------------------------------|-------------------------------|--------------------|\\n| Previous PE or DVT                                             | 3                             | 1                  |\\n| Heart rate                                                     |                               |                    |\\n|        75 - 94 b.p.m.                                         | 3                             | 1                  |\\n|        > 95 b.p.m.                                            | 5                             | 2                  |\\n| Surgery or fracture within the past month                      | 2                             | 1                  |\\n| Haemoptysis                                                    | 2                             | 1                  |\\n| Active cancer                                                  | 2                             | 1                  |\\n| Unilateral lower-limb pain                                     | 3                             | 1                  |\\n| Pain on lower-limb deep venous palpation and unilateral oedema | 4                             | 1                  |\\n| Age > 65 years                                                 | 1                             | 1                  |  \\n| Clinical probability                                           |                               |                    |\\n|----------------------------------------------------------------|-------------------------------|--------------------|\\n| Three-level score                                              |                               |                    |\\n|        Low                                                    | 0 - 3                         | 0 - 1              |\\n|        Intermediate                                           | 4 - 10                        | 2 - 4              |\\n|        High                                                   | > 11                          | > 5                |\\n| Two-level score                                                |                               |                    |\\n|        PE-unlikely                                            | 0 - 5                         | 0 - 2              |\\n|        PE-likely                                              | > 6                           | > 3                |  \\nb.p.m. = beats per minute; DVT = deep vein thrombosis; PE = pulmonary embolism.'),\n",
       "  Document(id='f031dec3-ae69-4478-883c-655f38546c82', metadata={'Figure/Table/SupplementaryTable': 'Supplementary Table 1', 'Section': '1 Supplementary Tables and Supplementary Figure', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): supplementary data', 'id': 'f031dec3-ae69-4478-883c-655f38546c82', 'source_file': 'salida_complementary.md'}, page_content='Supplementary Table 1: The Wells clinical prediction rule for pulmonary embolism\\n| Items                                             | Clinical decision rule points - Original version                                                  | Simplified version     |\\n|---------------------------------------------------|---------------------------------------------------------------------------------------------------|------------------------|\\n| Previous PE or DVT                                | 1.5                                                                                               | 1                      |\\n| Heart rate >100 b.p.m.                            | 1.5                                                                                               | 1                      |\\n| Surgery or immobilization within the past 4 weeks | 1.5                                                                                               | 1                      |\\n| Haemoptysis                                       | 1                                                                                                 | 1                      |\\n| Active cancer                                     | 1                                                                                                 | 1                      |\\n| Clinical signs of DVT                             | 3                                                                                                 | 1                      |\\n| Alterative diagnosis less likely than PE          | 3                                                                                                 | 1                      |  \\n| Clinical probability                              | Original Version                                                                                  | Simplified version     |\\n|---------------------------------------------------|---------------------------------------------------------------------------------------------------|------------------------|\\n| Three-level score                                 |                                                                                                   |                        |\\n| Low                                               | 0 - 1                                                                                             | N/A                    |\\n| Intermediate                                      | 2 - 6                                                                                             | N/A                    |\\n| High                                              | > \\\\_7                                                                                             | N/A                    |\\n| Two-level score                                   |                                                                                                   |                        |\\n| PE unlikely                                       | 0 - 4                                                                                             | 0 - 1                  |\\n| PE likely                                         | > \\\\_5                                                                                             | > \\\\_2                   |  \\n**Clinical probability**:  \\n- Original Version:\\n1. Three-level score:\\n- Low: 0 - 1\\n- Intermediate: 2 - 6\\n- High: > 6  \\n2. Two-level score:\\n- PE unlikely: 0 - 4\\n- PE likely: > 4  \\n- Simplified version:\\n1. Two-level score:\\n- PE unlikely: 0 - 1\\n- PE likely: > 1  \\nb.p.m. = beats per minute; DVT = deep vein thrombosis; N/A = not applicable; PE = pulmonary embolism.')],\n",
       " [Document(id='7e8aa6cf-f5ad-4ce0-bd85-166634be8a04', metadata={'Section': '4 Diagnosis', 'Subsection': '4.2 Assessment of clinical (pre-test) probability', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '7e8aa6cf-f5ad-4ce0-bd85-166634be8a04', 'source_file': 'Protocolo_v1_images.md'}, page_content='The combination of symptoms and clinical findings with the presence of predisposing factors for VTE allows the classification of patients with suspected PE into distinct categories of clinical or pre-test probability, which correspond to an increasing actual prevalence of confirmed PE. This pre-test assessment can be done either by implicit (empirical) clinical judgement or by using prediction rules. As the post-test (i.e. after an imaging test) probability of PE depends not only on the characteristics of the diagnostic test itself but also on the pretest probability, this is a key step in all diagnostic algorithms for PE.  \\nThe value of empirical clinical judgement has been confirmed in several large series. Clinical judgement usually includes commonplace tests such as chest X-rays and electrocardiograms for differential diagnosis. However, as clinical judgement lacks standardization, several explicit clinical prediction rules have been developed. Of these, the most frequently used prediction rules are the revised Geneva rule ( Table 5 ) and the Wells rule (see Supplementary Data Table 1). Both prediction rules have been simplified in an attempt to increase their adoption into clinical practice; the simplified versions have been externally validated.  \\nRegardless of the score used, the proportion of patients with confirmed PE can be expected to be ~ 10% in the low-probability category, 30% in the moderate-probability category, and 65% in the highprobability category. When the two-level classification is used, the proportion of patients with confirmed PE is ~ 12% in the PE-unlikely category and 30% in the PE-likely category. A direct prospective comparison of these rules confirmed a similar diagnostic performance.'),\n",
       "  Document(id='a992408d-41e8-4c55-a1cc-a91f08191813', metadata={'Figure/Table/SupplementaryTable': 'Table 5', 'Section': '4 Diagnosis', 'Subsection': '4.1 Clinical presentation', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': 'a992408d-41e8-4c55-a1cc-a91f08191813', 'source_file': 'Protocolo_v1_images.md'}, page_content='Table 5: The revised Geneva clinical prediction rule for pulmonary embolism\\n| Items                                                          | Clinical decision rule points | Simplified Version |\\n|----------------------------------------------------------------|-------------------------------|--------------------|\\n| Previous PE or DVT                                             | 3                             | 1                  |\\n| Heart rate                                                     |                               |                    |\\n|        75 - 94 b.p.m.                                         | 3                             | 1                  |\\n|        > 95 b.p.m.                                            | 5                             | 2                  |\\n| Surgery or fracture within the past month                      | 2                             | 1                  |\\n| Haemoptysis                                                    | 2                             | 1                  |\\n| Active cancer                                                  | 2                             | 1                  |\\n| Unilateral lower-limb pain                                     | 3                             | 1                  |\\n| Pain on lower-limb deep venous palpation and unilateral oedema | 4                             | 1                  |\\n| Age > 65 years                                                 | 1                             | 1                  |  \\n| Clinical probability                                           |                               |                    |\\n|----------------------------------------------------------------|-------------------------------|--------------------|\\n| Three-level score                                              |                               |                    |\\n|        Low                                                    | 0 - 3                         | 0 - 1              |\\n|        Intermediate                                           | 4 - 10                        | 2 - 4              |\\n|        High                                                   | > 11                          | > 5                |\\n| Two-level score                                                |                               |                    |\\n|        PE-unlikely                                            | 0 - 5                         | 0 - 2              |\\n|        PE-likely                                              | > 6                           | > 3                |  \\nb.p.m. = beats per minute; DVT = deep vein thrombosis; PE = pulmonary embolism.')]]"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "event['retrieved_information']"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Patient Clinical Metrics"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{}"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "event['metrics']"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Guidelines Consultation Response"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[GuidelinesConsultationResponse(content='The guidelines present two main clinical prediction rules to evaluate the risk of pulmonary embolism (PE) in patients: the revised Geneva score and the Wells score. Both scores combine clinical symptoms, signs, and predisposing factors to classify patients into categories of clinical or pre-test probability of PE.\\n\\n1. Revised Geneva Score:\\n- It includes items such as previous PE or deep vein thrombosis (DVT), heart rate ranges, recent surgery or fracture, hemoptysis, active cancer, unilateral lower-limb pain, signs of deep venous thrombosis, and age over 65 years.\\n- The score can be used in a three-level classification (low, intermediate, high probability) or a two-level classification (PE-unlikely, PE-likely).\\n- Simplified versions of the score exist to facilitate clinical use.\\n- The approximate prevalence of confirmed PE is about 10% in low probability, 30% in intermediate, and 65% in high probability categories.\\n\\n2. Wells Score:\\n- It includes previous PE or DVT, heart rate >100 bpm, recent surgery or immobilization, hemoptysis, active cancer, clinical signs of DVT, and whether an alternative diagnosis is less likely than PE.\\n- The Wells score also has an original and a simplified version.\\n- It can be applied as a three-level score (low, intermediate, high probability) or a two-level score (PE unlikely, PE likely).\\n- The simplified version mainly uses a two-level classification.\\n\\nBoth scores have been externally validated and show similar diagnostic performance. They are essential in the diagnostic algorithm for PE because the post-test probability after imaging depends on the pre-test probability assessed by these scores or clinical judgment.\\n\\nIn summary, the guidelines recommend using the revised Geneva score and the Wells score, both available in original and simplified forms, to stratify patients suspected of PE into risk categories that guide further diagnostic and management steps.', additional_kwargs={}, response_metadata={}, id='33152446-9a89-4840-8fa9-2c784f73f337', sources=[[Document(id='7e8aa6cf-f5ad-4ce0-bd85-166634be8a04', metadata={'Section': '4 Diagnosis', 'Subsection': '4.2 Assessment of clinical (pre-test) probability', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '7e8aa6cf-f5ad-4ce0-bd85-166634be8a04', 'source_file': 'Protocolo_v1_images.md'}, page_content='The combination of symptoms and clinical findings with the presence of predisposing factors for VTE allows the classification of patients with suspected PE into distinct categories of clinical or pre-test probability, which correspond to an increasing actual prevalence of confirmed PE. This pre-test assessment can be done either by implicit (empirical) clinical judgement or by using prediction rules. As the post-test (i.e. after an imaging test) probability of PE depends not only on the characteristics of the diagnostic test itself but also on the pretest probability, this is a key step in all diagnostic algorithms for PE.  \\nThe value of empirical clinical judgement has been confirmed in several large series. Clinical judgement usually includes commonplace tests such as chest X-rays and electrocardiograms for differential diagnosis. However, as clinical judgement lacks standardization, several explicit clinical prediction rules have been developed. Of these, the most frequently used prediction rules are the revised Geneva rule ( Table 5 ) and the Wells rule (see Supplementary Data Table 1). Both prediction rules have been simplified in an attempt to increase their adoption into clinical practice; the simplified versions have been externally validated.  \\nRegardless of the score used, the proportion of patients with confirmed PE can be expected to be ~ 10% in the low-probability category, 30% in the moderate-probability category, and 65% in the highprobability category. When the two-level classification is used, the proportion of patients with confirmed PE is ~ 12% in the PE-unlikely category and 30% in the PE-likely category. A direct prospective comparison of these rules confirmed a similar diagnostic performance.'), Document(id='a992408d-41e8-4c55-a1cc-a91f08191813', metadata={'Figure/Table/SupplementaryTable': 'Table 5', 'Section': '4 Diagnosis', 'Subsection': '4.1 Clinical presentation', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': 'a992408d-41e8-4c55-a1cc-a91f08191813', 'source_file': 'Protocolo_v1_images.md'}, page_content='Table 5: The revised Geneva clinical prediction rule for pulmonary embolism\\n| Items                                                          | Clinical decision rule points | Simplified Version |\\n|----------------------------------------------------------------|-------------------------------|--------------------|\\n| Previous PE or DVT                                             | 3                             | 1                  |\\n| Heart rate                                                     |                               |                    |\\n|        75 - 94 b.p.m.                                         | 3                             | 1                  |\\n|        > 95 b.p.m.                                            | 5                             | 2                  |\\n| Surgery or fracture within the past month                      | 2                             | 1                  |\\n| Haemoptysis                                                    | 2                             | 1                  |\\n| Active cancer                                                  | 2                             | 1                  |\\n| Unilateral lower-limb pain                                     | 3                             | 1                  |\\n| Pain on lower-limb deep venous palpation and unilateral oedema | 4                             | 1                  |\\n| Age > 65 years                                                 | 1                             | 1                  |  \\n| Clinical probability                                           |                               |                    |\\n|----------------------------------------------------------------|-------------------------------|--------------------|\\n| Three-level score                                              |                               |                    |\\n|        Low                                                    | 0 - 3                         | 0 - 1              |\\n|        Intermediate                                           | 4 - 10                        | 2 - 4              |\\n|        High                                                   | > 11                          | > 5                |\\n| Two-level score                                                |                               |                    |\\n|        PE-unlikely                                            | 0 - 5                         | 0 - 2              |\\n|        PE-likely                                              | > 6                           | > 3                |  \\nb.p.m. = beats per minute; DVT = deep vein thrombosis; PE = pulmonary embolism.'), Document(id='f031dec3-ae69-4478-883c-655f38546c82', metadata={'Figure/Table/SupplementaryTable': 'Supplementary Table 1', 'Section': '1 Supplementary Tables and Supplementary Figure', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): supplementary data', 'id': 'f031dec3-ae69-4478-883c-655f38546c82', 'source_file': 'salida_complementary.md'}, page_content='Supplementary Table 1: The Wells clinical prediction rule for pulmonary embolism\\n| Items                                             | Clinical decision rule points - Original version                                                  | Simplified version     |\\n|---------------------------------------------------|---------------------------------------------------------------------------------------------------|------------------------|\\n| Previous PE or DVT                                | 1.5                                                                                               | 1                      |\\n| Heart rate >100 b.p.m.                            | 1.5                                                                                               | 1                      |\\n| Surgery or immobilization within the past 4 weeks | 1.5                                                                                               | 1                      |\\n| Haemoptysis                                       | 1                                                                                                 | 1                      |\\n| Active cancer                                     | 1                                                                                                 | 1                      |\\n| Clinical signs of DVT                             | 3                                                                                                 | 1                      |\\n| Alterative diagnosis less likely than PE          | 3                                                                                                 | 1                      |  \\n| Clinical probability                              | Original Version                                                                                  | Simplified version     |\\n|---------------------------------------------------|---------------------------------------------------------------------------------------------------|------------------------|\\n| Three-level score                                 |                                                                                                   |                        |\\n| Low                                               | 0 - 1                                                                                             | N/A                    |\\n| Intermediate                                      | 2 - 6                                                                                             | N/A                    |\\n| High                                              | > \\\\_7                                                                                             | N/A                    |\\n| Two-level score                                   |                                                                                                   |                        |\\n| PE unlikely                                       | 0 - 4                                                                                             | 0 - 1                  |\\n| PE likely                                         | > \\\\_5                                                                                             | > \\\\_2                   |  \\n**Clinical probability**:  \\n- Original Version:\\n1. Three-level score:\\n- Low: 0 - 1\\n- Intermediate: 2 - 6\\n- High: > 6  \\n2. Two-level score:\\n- PE unlikely: 0 - 4\\n- PE likely: > 4  \\n- Simplified version:\\n1. Two-level score:\\n- PE unlikely: 0 - 1\\n- PE likely: > 1  \\nb.p.m. = beats per minute; DVT = deep vein thrombosis; N/A = not applicable; PE = pulmonary embolism.')], [Document(id='7e8aa6cf-f5ad-4ce0-bd85-166634be8a04', metadata={'Section': '4 Diagnosis', 'Subsection': '4.2 Assessment of clinical (pre-test) probability', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '7e8aa6cf-f5ad-4ce0-bd85-166634be8a04', 'source_file': 'Protocolo_v1_images.md'}, page_content='The combination of symptoms and clinical findings with the presence of predisposing factors for VTE allows the classification of patients with suspected PE into distinct categories of clinical or pre-test probability, which correspond to an increasing actual prevalence of confirmed PE. This pre-test assessment can be done either by implicit (empirical) clinical judgement or by using prediction rules. As the post-test (i.e. after an imaging test) probability of PE depends not only on the characteristics of the diagnostic test itself but also on the pretest probability, this is a key step in all diagnostic algorithms for PE.  \\nThe value of empirical clinical judgement has been confirmed in several large series. Clinical judgement usually includes commonplace tests such as chest X-rays and electrocardiograms for differential diagnosis. However, as clinical judgement lacks standardization, several explicit clinical prediction rules have been developed. Of these, the most frequently used prediction rules are the revised Geneva rule ( Table 5 ) and the Wells rule (see Supplementary Data Table 1). Both prediction rules have been simplified in an attempt to increase their adoption into clinical practice; the simplified versions have been externally validated.  \\nRegardless of the score used, the proportion of patients with confirmed PE can be expected to be ~ 10% in the low-probability category, 30% in the moderate-probability category, and 65% in the highprobability category. When the two-level classification is used, the proportion of patients with confirmed PE is ~ 12% in the PE-unlikely category and 30% in the PE-likely category. A direct prospective comparison of these rules confirmed a similar diagnostic performance.'), Document(id='a992408d-41e8-4c55-a1cc-a91f08191813', metadata={'Figure/Table/SupplementaryTable': 'Table 5', 'Section': '4 Diagnosis', 'Subsection': '4.1 Clinical presentation', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': 'a992408d-41e8-4c55-a1cc-a91f08191813', 'source_file': 'Protocolo_v1_images.md'}, page_content='Table 5: The revised Geneva clinical prediction rule for pulmonary embolism\\n| Items                                                          | Clinical decision rule points | Simplified Version |\\n|----------------------------------------------------------------|-------------------------------|--------------------|\\n| Previous PE or DVT                                             | 3                             | 1                  |\\n| Heart rate                                                     |                               |                    |\\n|        75 - 94 b.p.m.                                         | 3                             | 1                  |\\n|        > 95 b.p.m.                                            | 5                             | 2                  |\\n| Surgery or fracture within the past month                      | 2                             | 1                  |\\n| Haemoptysis                                                    | 2                             | 1                  |\\n| Active cancer                                                  | 2                             | 1                  |\\n| Unilateral lower-limb pain                                     | 3                             | 1                  |\\n| Pain on lower-limb deep venous palpation and unilateral oedema | 4                             | 1                  |\\n| Age > 65 years                                                 | 1                             | 1                  |  \\n| Clinical probability                                           |                               |                    |\\n|----------------------------------------------------------------|-------------------------------|--------------------|\\n| Three-level score                                              |                               |                    |\\n|        Low                                                    | 0 - 3                         | 0 - 1              |\\n|        Intermediate                                           | 4 - 10                        | 2 - 4              |\\n|        High                                                   | > 11                          | > 5                |\\n| Two-level score                                                |                               |                    |\\n|        PE-unlikely                                            | 0 - 5                         | 0 - 2              |\\n|        PE-likely                                              | > 6                           | > 3                |  \\nb.p.m. = beats per minute; DVT = deep vein thrombosis; PE = pulmonary embolism.')]], query='Which scores can we find in the guidelines to evaluate the risk of the PE on a patient?')]"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "event['guidelines_consultation_responses']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Guidelines Consultation Response:\n",
      "\n",
      "Query: Which scores can we find in the guidelines to evaluate the risk of the PE on a patient?\n",
      "\n",
      "Response: The guidelines present two main clinical prediction rules to evaluate the risk of pulmonary embolism (PE) in patients: the revised Geneva score and the Wells score. Both scores combine clinical symptoms, signs, and predisposing factors to classify patients into categories of clinical or pre-test probability of PE.\n",
      "\n",
      "1. Revised Geneva Score:\n",
      "- It includes items such as previous PE or deep vein thrombosis (DVT), heart rate ranges, recent surgery or fracture, hemoptysis, active cancer, unilateral lower-limb pain, signs of deep venous thrombosis, and age over 65 years.\n",
      "- The score can be used in a three-level classification (low, intermediate, high probability) or a two-level classification (PE-unlikely, PE-likely).\n",
      "- Simplified versions of the score exist to facilitate clinical use.\n",
      "- The approximate prevalence of confirmed PE is about 10% in low probability, 30% in intermediate, and 65% in high probability categories.\n",
      "\n",
      "2. Wells Score:\n",
      "- It includes previous PE or DVT, heart rate >100 bpm, recent surgery or immobilization, hemoptysis, active cancer, clinical signs of DVT, and whether an alternative diagnosis is less likely than PE.\n",
      "- The Wells score also has an original and a simplified version.\n",
      "- It can be applied as a three-level score (low, intermediate, high probability) or a two-level score (PE unlikely, PE likely).\n",
      "- The simplified version mainly uses a two-level classification.\n",
      "\n",
      "Both scores have been externally validated and show similar diagnostic performance. They are essential in the diagnostic algorithm for PE because the post-test probability after imaging depends on the pre-test probability assessed by these scores or clinical judgment.\n",
      "\n",
      "In summary, the guidelines recommend using the revised Geneva score and the Wells score, both available in original and simplified forms, to stratify patients suspected of PE into risk categories that guide further diagnostic and management steps.\n",
      "\n",
      "Sources: [[Document(id='7e8aa6cf-f5ad-4ce0-bd85-166634be8a04', metadata={'Section': '4 Diagnosis', 'Subsection': '4.2 Assessment of clinical (pre-test) probability', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '7e8aa6cf-f5ad-4ce0-bd85-166634be8a04', 'source_file': 'Protocolo_v1_images.md'}, page_content='The combination of symptoms and clinical findings with the presence of predisposing factors for VTE allows the classification of patients with suspected PE into distinct categories of clinical or pre-test probability, which correspond to an increasing actual prevalence of confirmed PE. This pre-test assessment can be done either by implicit (empirical) clinical judgement or by using prediction rules. As the post-test (i.e. after an imaging test) probability of PE depends not only on the characteristics of the diagnostic test itself but also on the pretest probability, this is a key step in all diagnostic algorithms for PE.  \\nThe value of empirical clinical judgement has been confirmed in several large series. Clinical judgement usually includes commonplace tests such as chest X-rays and electrocardiograms for differential diagnosis. However, as clinical judgement lacks standardization, several explicit clinical prediction rules have been developed. Of these, the most frequently used prediction rules are the revised Geneva rule ( Table 5 ) and the Wells rule (see Supplementary Data Table 1). Both prediction rules have been simplified in an attempt to increase their adoption into clinical practice; the simplified versions have been externally validated.  \\nRegardless of the score used, the proportion of patients with confirmed PE can be expected to be ~ 10% in the low-probability category, 30% in the moderate-probability category, and 65% in the highprobability category. When the two-level classification is used, the proportion of patients with confirmed PE is ~ 12% in the PE-unlikely category and 30% in the PE-likely category. A direct prospective comparison of these rules confirmed a similar diagnostic performance.'), Document(id='a992408d-41e8-4c55-a1cc-a91f08191813', metadata={'Figure/Table/SupplementaryTable': 'Table 5', 'Section': '4 Diagnosis', 'Subsection': '4.1 Clinical presentation', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': 'a992408d-41e8-4c55-a1cc-a91f08191813', 'source_file': 'Protocolo_v1_images.md'}, page_content='Table 5: The revised Geneva clinical prediction rule for pulmonary embolism\\n| Items                                                          | Clinical decision rule points | Simplified Version |\\n|----------------------------------------------------------------|-------------------------------|--------------------|\\n| Previous PE or DVT                                             | 3                             | 1                  |\\n| Heart rate                                                     |                               |                    |\\n|        75 - 94 b.p.m.                                         | 3                             | 1                  |\\n|        > 95 b.p.m.                                            | 5                             | 2                  |\\n| Surgery or fracture within the past month                      | 2                             | 1                  |\\n| Haemoptysis                                                    | 2                             | 1                  |\\n| Active cancer                                                  | 2                             | 1                  |\\n| Unilateral lower-limb pain                                     | 3                             | 1                  |\\n| Pain on lower-limb deep venous palpation and unilateral oedema | 4                             | 1                  |\\n| Age > 65 years                                                 | 1                             | 1                  |  \\n| Clinical probability                                           |                               |                    |\\n|----------------------------------------------------------------|-------------------------------|--------------------|\\n| Three-level score                                              |                               |                    |\\n|        Low                                                    | 0 - 3                         | 0 - 1              |\\n|        Intermediate                                           | 4 - 10                        | 2 - 4              |\\n|        High                                                   | > 11                          | > 5                |\\n| Two-level score                                                |                               |                    |\\n|        PE-unlikely                                            | 0 - 5                         | 0 - 2              |\\n|        PE-likely                                              | > 6                           | > 3                |  \\nb.p.m. = beats per minute; DVT = deep vein thrombosis; PE = pulmonary embolism.'), Document(id='f031dec3-ae69-4478-883c-655f38546c82', metadata={'Figure/Table/SupplementaryTable': 'Supplementary Table 1', 'Section': '1 Supplementary Tables and Supplementary Figure', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): supplementary data', 'id': 'f031dec3-ae69-4478-883c-655f38546c82', 'source_file': 'salida_complementary.md'}, page_content='Supplementary Table 1: The Wells clinical prediction rule for pulmonary embolism\\n| Items                                             | Clinical decision rule points - Original version                                                  | Simplified version     |\\n|---------------------------------------------------|---------------------------------------------------------------------------------------------------|------------------------|\\n| Previous PE or DVT                                | 1.5                                                                                               | 1                      |\\n| Heart rate >100 b.p.m.                            | 1.5                                                                                               | 1                      |\\n| Surgery or immobilization within the past 4 weeks | 1.5                                                                                               | 1                      |\\n| Haemoptysis                                       | 1                                                                                                 | 1                      |\\n| Active cancer                                     | 1                                                                                                 | 1                      |\\n| Clinical signs of DVT                             | 3                                                                                                 | 1                      |\\n| Alterative diagnosis less likely than PE          | 3                                                                                                 | 1                      |  \\n| Clinical probability                              | Original Version                                                                                  | Simplified version     |\\n|---------------------------------------------------|---------------------------------------------------------------------------------------------------|------------------------|\\n| Three-level score                                 |                                                                                                   |                        |\\n| Low                                               | 0 - 1                                                                                             | N/A                    |\\n| Intermediate                                      | 2 - 6                                                                                             | N/A                    |\\n| High                                              | > \\\\_7                                                                                             | N/A                    |\\n| Two-level score                                   |                                                                                                   |                        |\\n| PE unlikely                                       | 0 - 4                                                                                             | 0 - 1                  |\\n| PE likely                                         | > \\\\_5                                                                                             | > \\\\_2                   |  \\n**Clinical probability**:  \\n- Original Version:\\n1. Three-level score:\\n- Low: 0 - 1\\n- Intermediate: 2 - 6\\n- High: > 6  \\n2. Two-level score:\\n- PE unlikely: 0 - 4\\n- PE likely: > 4  \\n- Simplified version:\\n1. Two-level score:\\n- PE unlikely: 0 - 1\\n- PE likely: > 1  \\nb.p.m. = beats per minute; DVT = deep vein thrombosis; N/A = not applicable; PE = pulmonary embolism.')], [Document(id='7e8aa6cf-f5ad-4ce0-bd85-166634be8a04', metadata={'Section': '4 Diagnosis', 'Subsection': '4.2 Assessment of clinical (pre-test) probability', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': '7e8aa6cf-f5ad-4ce0-bd85-166634be8a04', 'source_file': 'Protocolo_v1_images.md'}, page_content='The combination of symptoms and clinical findings with the presence of predisposing factors for VTE allows the classification of patients with suspected PE into distinct categories of clinical or pre-test probability, which correspond to an increasing actual prevalence of confirmed PE. This pre-test assessment can be done either by implicit (empirical) clinical judgement or by using prediction rules. As the post-test (i.e. after an imaging test) probability of PE depends not only on the characteristics of the diagnostic test itself but also on the pretest probability, this is a key step in all diagnostic algorithms for PE.  \\nThe value of empirical clinical judgement has been confirmed in several large series. Clinical judgement usually includes commonplace tests such as chest X-rays and electrocardiograms for differential diagnosis. However, as clinical judgement lacks standardization, several explicit clinical prediction rules have been developed. Of these, the most frequently used prediction rules are the revised Geneva rule ( Table 5 ) and the Wells rule (see Supplementary Data Table 1). Both prediction rules have been simplified in an attempt to increase their adoption into clinical practice; the simplified versions have been externally validated.  \\nRegardless of the score used, the proportion of patients with confirmed PE can be expected to be ~ 10% in the low-probability category, 30% in the moderate-probability category, and 65% in the highprobability category. When the two-level classification is used, the proportion of patients with confirmed PE is ~ 12% in the PE-unlikely category and 30% in the PE-likely category. A direct prospective comparison of these rules confirmed a similar diagnostic performance.'), Document(id='a992408d-41e8-4c55-a1cc-a91f08191813', metadata={'Figure/Table/SupplementaryTable': 'Table 5', 'Section': '4 Diagnosis', 'Subsection': '4.1 Clinical presentation', 'Title': '2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)', 'id': 'a992408d-41e8-4c55-a1cc-a91f08191813', 'source_file': 'Protocolo_v1_images.md'}, page_content='Table 5: The revised Geneva clinical prediction rule for pulmonary embolism\\n| Items                                                          | Clinical decision rule points | Simplified Version |\\n|----------------------------------------------------------------|-------------------------------|--------------------|\\n| Previous PE or DVT                                             | 3                             | 1                  |\\n| Heart rate                                                     |                               |                    |\\n|        75 - 94 b.p.m.                                         | 3                             | 1                  |\\n|        > 95 b.p.m.                                            | 5                             | 2                  |\\n| Surgery or fracture within the past month                      | 2                             | 1                  |\\n| Haemoptysis                                                    | 2                             | 1                  |\\n| Active cancer                                                  | 2                             | 1                  |\\n| Unilateral lower-limb pain                                     | 3                             | 1                  |\\n| Pain on lower-limb deep venous palpation and unilateral oedema | 4                             | 1                  |\\n| Age > 65 years                                                 | 1                             | 1                  |  \\n| Clinical probability                                           |                               |                    |\\n|----------------------------------------------------------------|-------------------------------|--------------------|\\n| Three-level score                                              |                               |                    |\\n|        Low                                                    | 0 - 3                         | 0 - 1              |\\n|        Intermediate                                           | 4 - 10                        | 2 - 4              |\\n|        High                                                   | > 11                          | > 5                |\\n| Two-level score                                                |                               |                    |\\n|        PE-unlikely                                            | 0 - 5                         | 0 - 2              |\\n|        PE-likely                                              | > 6                           | > 3                |  \\nb.p.m. = beats per minute; DVT = deep vein thrombosis; PE = pulmonary embolism.')]]\n"
     ]
    }
   ],
   "source": [
    "print('Guidelines Consultation Response:\\n')\n",
    "print(f'Query: {event[\"guidelines_consultation_responses\"][0].query}\\n')\n",
    "print(f'Response: {event[\"guidelines_consultation_responses\"][0].content}\\n')\n",
    "print(f'Sources: {event[\"guidelines_consultation_responses\"][0].sources}\\n')\n",
    "print(f'Hallucinations: {event[\"guidelines_consultation_responses\"][0].hallucinations}')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Clinical Case Evaluation Response"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[]"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "event['clinical_case_evaluation_reports']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "print('Guidelines Consultation Response:\\n')\n",
    "print(f'Query: {event[\"clinical_case_evaluation_reports\"][0].query}\\n')\n",
    "print(f'Response: {event[\"clinical_case_evaluation_reports\"][0].content}\\n')\n",
    "print(f'Sources: {event[\"clinical_case_evaluation_reports\"][0].sources}\\n')\n",
    "print(f'Hallucinations: {event[\"clinical_case_evaluation_reports\"][0].hallucinations}')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Results Extraction"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# import json\n",
    "# import os"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Guidelines Consultation "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# def create_evaluation_dataset_from_excel(excel_path, output_json_path=\"experimental_results\\guidelines_consultation_results\\guidelines_consultation_results_dataset.json\", sheet_name=None):\n",
    "#     \"\"\"\n",
    "#     Creates a JSON file with evaluation entries by reading data from an Excel file.\n",
    "\n",
    "#     Args:\n",
    "#         excel_path (str): Path to the Excel file.\n",
    "#         output_json_path (str): Path to save the JSON file.\n",
    "#         sheet_name (str, optional): Name of the sheet to read. If None, reads the first sheet.\n",
    "\n",
    "#     Returns:\n",
    "#         list: Created dataset as a list of dictionaries.\n",
    "#     \"\"\"\n",
    "\n",
    "#     try:\n",
    "#         # Read the Excel file\n",
    "#         if sheet_name:\n",
    "#             df = pd.read_excel(excel_path, sheet_name=sheet_name)\n",
    "#         else:\n",
    "#             df = pd.read_excel(excel_path)\n",
    "\n",
    "#         print(f\"Excel file read successfully. Rows: {len(df)}\")\n",
    "#         print(f\"Available columns: {list(df.columns)}\")\n",
    "\n",
    "#         # Check that the required columns exist\n",
    "#         required_columns = ['question', 'reference_answer']\n",
    "#         missing_columns = [col for col in required_columns if col not in df.columns]\n",
    "\n",
    "#         if missing_columns:\n",
    "#             raise ValueError(f\"Missing columns in Excel: {missing_columns}\")\n",
    "\n",
    "#         # Create the dataset\n",
    "#         dataset = []\n",
    "\n",
    "#         # Iterate over each row in the DataFrame\n",
    "#         for index, row in df.iterrows():\n",
    "#             # Create the entry with the required structure\n",
    "#             entry = {\n",
    "#                 \"user_input\": str(row[\"question\"]) if pd.notna(row[\"question\"]) else \"\",\n",
    "#                 \"reference\": str(row[\"reference_answer\"]) if pd.notna(row[\"reference_answer\"]) else \"\",\n",
    "#                 \"retrieved_contexts\": [],  # Will remain empty to be filled later\n",
    "#                 \"response\": \"\"  # Will remain empty to be filled later\n",
    "#             }\n",
    "\n",
    "#             dataset.append(entry)\n",
    "\n",
    "#         # Save the dataset to a JSON file\n",
    "#         with open(output_json_path, \"w\", encoding=\"utf-8\") as f:\n",
    "#             json.dump(dataset, f, ensure_ascii=False, indent=4)\n",
    "\n",
    "#         print(f\"Dataset successfully created at: {output_json_path}\")\n",
    "#         print(f\"Total entries: {len(dataset)}\")\n",
    "\n",
    "#         return dataset\n",
    "\n",
    "#     except FileNotFoundError:\n",
    "#         print(f\"Error: File not found {excel_path}\")\n",
    "#         return []\n",
    "#     except Exception as e:\n",
    "#         print(f\"Error processing the file: {str(e)}\")\n",
    "#         return []"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# excel_file = \"experimental_results\\guidelines_consultation_results\\evaluation_questions\\preguntas_gt_tep.xlsx\"\n",
    "# dataset = create_evaluation_dataset_from_excel(\n",
    "#     excel_path=excel_file\n",
    "# )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# # Function to update the dataset later\n",
    "# def update_dataset_entry(json_path, entry_index, retrieved_contexts=None, response=None):\n",
    "#     \"\"\"\n",
    "#     Updates a specific entry in the dataset with retrieved_contexts and/or response.\n",
    "    \n",
    "#     Args:\n",
    "#         json_path (str): Path to the dataset JSON file\n",
    "#         entry_index (int): Index of the entry to update\n",
    "#         retrieved_contexts (list, optional): List of retrieved contexts\n",
    "#         response (str, optional): Generated response\n",
    "#     \"\"\"\n",
    "#     try:\n",
    "#         # Read the existing dataset\n",
    "#         with open(json_path, \"r\", encoding=\"utf-8\") as f:\n",
    "#             dataset = json.load(f)\n",
    "        \n",
    "#         # Check that the index is valid\n",
    "#         if entry_index < 0 or entry_index >= len(dataset):\n",
    "#             print(f\"Error: Index {entry_index} out of range. The dataset has {len(dataset)} entries.\")\n",
    "#             return False\n",
    "        \n",
    "#         # Update the entry\n",
    "#         if retrieved_contexts is not None:\n",
    "#             dataset[entry_index][\"retrieved_contexts\"] = retrieved_contexts\n",
    "        \n",
    "#         if response is not None:\n",
    "#             dataset[entry_index][\"response\"] = response\n",
    "        \n",
    "#         # Save the updated dataset\n",
    "#         with open(json_path, \"w\", encoding=\"utf-8\") as f:\n",
    "#             json.dump(dataset, f, ensure_ascii=False, indent=4)\n",
    "        \n",
    "#         print(f\"Entry {entry_index} updated successfully.\")\n",
    "#         return True\n",
    "        \n",
    "#     except Exception as e:\n",
    "#         print(f\"Error updating the entry: {str(e)}\")\n",
    "#         return False"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# response = event['guidelines_consultation_responses'][0].content\n",
    "# retrieved_docs = event['guidelines_consultation_responses'][0].sources\n",
    "\n",
    "# # Extract page_content from all documents in retrieved_docs\n",
    "# page_contents = []\n",
    "\n",
    "# for doc_list in retrieved_docs:\n",
    "#     for doc in doc_list:\n",
    "#         page_contents.append(doc.page_content)\n",
    "\n",
    "# print(f\"Total page contents extracted: {len(page_contents)}\")\n",
    "# print(f\"First few characters of each page content:\")\n",
    "# for i, content in enumerate(page_contents):\n",
    "#     print(f\"Document {i+1}: {content[:100]}...\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# update_dataset_entry(\n",
    "#     json_path=\"experimental_results\\guidelines_consultation_results\\guidelines_consultation_results_dataset.json\",\n",
    "#     entry_index=0, # Adjust the index as needed\n",
    "#     retrieved_contexts=page_contents,\n",
    "#     response=response\n",
    "# )"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Clinical Case Evaluation Report "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# def save_recommendations_to_json(clinical_case_evaluation_report, filename=\"experimental_results/clinical_case_evaluation_results/clinical_case_evaluation_dataset.json\"):\n",
    "#     \"\"\"\n",
    "#     Save the recommendation object to a JSON file.\n",
    "#     If the file already exists, append the new recommendation rather than overwriting.\n",
    "    \n",
    "#     Args:\n",
    "#         recommendation: The recommendation object containing content, sources, query, and hallucinations\n",
    "#         filename: The name of the file to save the recommendations to\n",
    "#     \"\"\"\n",
    "#     # Create a dictionary to store the recommendation data\n",
    "#     extracted_report = {\n",
    "#         \"content\": clinical_case_evaluation_report.content,\n",
    "#         \"query\": clinical_case_evaluation_report.query,\n",
    "#         \"hallucinations\": clinical_case_evaluation_report.hallucinations,\n",
    "#         \"sources\": [\n",
    "#             {\n",
    "#                 \"content\": source.page_content,\n",
    "#                 \"metadata\": source.metadata\n",
    "#             } for source in clinical_case_evaluation_report.sources\n",
    "#         ]\n",
    "#     }\n",
    "    \n",
    "#     # Check if file already exists\n",
    "#     if os.path.exists(filename):\n",
    "#         # Read existing data\n",
    "#         with open(filename, 'r', encoding='utf-8') as f:\n",
    "#             try:\n",
    "#                 existing_data = json.load(f)\n",
    "#                 if not isinstance(existing_data, list):\n",
    "#                     # Convert to list if not already\n",
    "#                     existing_data = [existing_data]\n",
    "#             except json.JSONDecodeError:\n",
    "#                 # If file is empty or invalid JSON, start with empty list\n",
    "#                 existing_data = []\n",
    "        \n",
    "#         # Append new recommendation\n",
    "#         existing_data.append(extracted_report)\n",
    "#         data_to_save = existing_data\n",
    "#     else:\n",
    "#         # Create new file with recommendation as first item in a list\n",
    "#         data_to_save = [extracted_report]\n",
    "    \n",
    "#     # Save the updated data to the JSON file\n",
    "#     with open(filename, 'w', encoding='utf-8') as f:\n",
    "#         json.dump(data_to_save, f, indent=4, ensure_ascii=False)\n",
    "    \n",
    "#     print(f\"Recommendation successfully saved to {filename} (total: {len(data_to_save)})\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# save_recommendations_to_json(event['clinical_case_evaluation_reports'][0])"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "paper-2",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
